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1. INTRODUCTION 
 
Modern nanotechnology is a dynamic field, multidisciplinary in nature. Even if the interest in 
nano-scale products has increased more and more especially in recent years, Mother Nature 
was the first scientist offering nano-materials. For example, Ayurveda, the ancient traditional 
system of medicine in India, has described and used several “bhasmas”, which were 
characterized by nanoparticles.  
The first definition of modern nanotechnology was explained in 1959 by Richard Feynman at the 
annual meeting of the American Physical Society: “There’s plenty of room at the bottom”. 
However, the actual term nanotechnology was defined only in 1974 by Norio Taniguchi from 
Japan in a paper in which he declared: "Nano-technology mainly consists of the processing of 
separation, consolidation, and deformation of materials by one atom or by one molecule." 
The interest in interface and colloid science together with the development of analytical tools, 
such as the scanning tunnelling microscope in 1981 and the atomic force microscope in 1986, 
fed the impetus for modern nanotechnology. 
Nowadays, everyone feels the impact of nanotechnology in his life. There is a trend that urges 
people to revisit many research areas with a nano-view, in order to understand how the same 
thing can work at nano- level. This phenomenon is revolutionizing pharmaceutical sciences and 
many drugs are being reformulated for possibilities of delivering as a nanosystem. 
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1.1 NANOCARRIERS AND DRUG DELIVERY 
The concept of nanoparticles and drug targeting was inspired by a visit of Paul Erlich to Karl 
Maria von Weber’s opera “Der Freishütz” [1]. In this opera, a so-called “Freikugeln” or flying 
bullets, made by calling the spirit of the devil, play a central role. Ehrlich after attending this 
opera thought that this concept of targeted delivery could greatly improve drug therapy. He 
called the delivery system that would be used in therapy “Magic Bullets”. Notwithstanding Erlich 
as a medical doctor, with a great interest in bacteriology and immunology, had something like 
antibodies in mind, this idea lead to the concept of nanoparticles and of drug targeting. 
The nanoscopic era of targeted nano-carriers, linked to the concept of “Magic bullet”, began 
with systems proposed in the 1970s and presently is evolving into many exciting and clinically 
successful products in the 2000s [2]. 
In fact, especially in recent years, studies have revealed that an increasing number of new 
molecular entities (NMEs) suffer from undesirable physicochemical and biopharmaceutical 
properties, even if they have been selected for full scale development thanks to their safety and 
pharmacological data. Poor water solubility, insufficient bioavailability, high food dependency or 
fluctuating plasma levels are the main and common problems. Thus, it becomes evident that the 
development of new drugs alone is not sufficient to ensure progress in drug therapy. 
In this field, colloidal carriers have attracted the main interest because they fulfil the 
characteristics of non-toxicity, sufficient drug-loading capacity, possibility of drug targeting, 
chemical and physical storage stability, controlled release characteristics and feasibility of 
scaling up production [3-5]. 
Among colloidal carriers, nanosized systems have a preeminent position because of their 
capability in increasing the solubility and therefore the bioavailability of poorly water-soluble 
substances [6-8]. 
The field of drug delivery has also attracted the attention of pharmaceutical industry because it 
offers a strategic tool to expand current drug markets; new delivery technologies could 
repackage classic drugs, thus providing a competitive edge after the expiration of patents and 
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preclude completion from generics. Targeted drug systems can convey drugs more effectively 
and conveniently than those of the past, increase patient compliance, extend the product life 
cycle, provide product differentiation and reduce healthcare costs [9]. 
In addition, novel drug delivery systems would offer protection and improvement of the 
pharmacokinetics of easily degradable molecules, such as peptides and proteins often 
displaying short half-lives in vivo [10,11]. Therefore, the development of techniques that could 
selectively deliver drugs to the pathological sites is currently one of the most important areas of 
drug research. The emergence of nanotechnology is likely to have a significant impact on the 
drug delivery sector and nanoparticles (NPs) are at the leading edge, with many potential 
applications in clinical medicine and research [12]. NPs can be correctly considered as the 
future of drug delivery technology as they have the potential to become useful therapeutic and 
diagnostic tools in the near future. 
Nanometric carriers might differ in composition, materials, application spectrum and drug 
loading and concerning their different characteristics, they should be employed for various 
administration routes. Parenteral [13], dermal [14-16], oral [17,18], ocular [19] and pulmonary 
[20] applications have been widely studied for NPs. In all cases, one of the major advantages 
that nanotechnology offers is targeted drug delivery to the site of disease. This can be achieved 
either through passive targeting of drugs to the site of action or by active targeting of the drug 
(Fig. 1). 
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Figure 1. Schematic representation of different drug-targeting approaches. 
 
 
1.1.1 Passive tageting 
Passive targeting can be divided in EPR effect and localized delivery. 
In the first case, targeting exploits the anatomical differences between normal and diseased 
tissues to deliver the drugs to the required site. In fact, the physiology of diseased tissues may 
be altered in a variety of physiological conditions through the enhanced permeability and 
retention (EPR) effect [21,22]. This phenomenon occurs because tumour vasculature is leaky 
and as consequence, circulating NPs can accumulate more in the tumour tissues than in normal 
tissues. Besides exploiting the structural framework of cancerous tissues, the EPR effect is also 
observed at the site of inflammation. 
In the second case, the approach is the direct intratumour delivery of anticancer agents using 
NPs, which can be used in the treatment of local cancers (prostate, head, neck). Recently it has 
been demonstrated that transferrin conjugated anticancer drug loaded biodegradable NPs are 
more effective in demonstrating the antiproliferative effect of the drug than its solution or with 
unconjugated NPs [23]. The better efficacy of conjugated NPs was due to their greater cellular 
uptake and sustained intracellular retention than unconjugated NPs or the drug in solution. 
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1.1.2 Active targeting 
Active targeting, on the other hand, requires the conjugation of receptor specific ligands that can 
promote site specific targeting [24,25]. The success of drug targeting depends on the selection 
of the targeting moiety, which should be abundant, have high affinity and specificity of binding to 
cell surface receptors and should be well suited to chemical modification by conjugation. The 
active targeting depends on molecular recognition of the diseased cells by various signature 
molecules overexpressed at the diseased site either via ligand-receptor, antigen-antibody 
interactions or by targeting through aptamers. 
Conjugating the carrier with a cell or tissue-specific ligand, thereby allowing a preferential 
accumulation of the drug at the diseased site, can actively target the therapeutic agent. 
Thus, the submicron size range of nanosystems as well as the ability to couple/conjugate 
different targeting ligands offer excellent opportunities to pass the physiological barriers and 
access different tissues followed by an efficient cellular uptake and intracellular internalization; 
various nanosystems can be accumulated at higher concentrations than normal drug. 
 
 
1.2 APPLICATIONS OF NANOPARTICLES IN MEDICINE 
The use of NPs in medicine is widespread. Especially in recent years, nanoparticulate systems 
are used not only for therapeutic applications, but also in diagnostics and imaging fields. 
 
1.2.1 Therapeutics 
The therapeutic applications of NPs are different, ranging from cancer therapeutics, 
antimicrobial actions, vaccine delivery, gene delivery and site-specific targeting to avoid the 
undesirable side effects of the current therapies. Many chemotherapeutic agents such as 
carboplatin, paclitaxel, doxorubicin and etoposide, etc., have been successfully loaded to NPs 
and the obtained nanopaticulate systems resulted very potent against various cancers [26]. 
In addition, NPs with surface-functionalised biomolecules have also been synthesized and are 
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studied as potential therapeutic agents. Functionalised NPs have also been used for targeted 
gene silencing or as therapeutics due to their antimicrobial properties. 
 
1.2.2 Diagnostics 
Nanomaterials and nanotechnology combined with modern instrumentation have the potential to 
understand biology and medicine at the molecular level with accurate quantification. These 
analyses can be possible with the aid of a variety of nanomaterials for multiplex diagnostics and 
thus can offer sensitive, rapid and cost effective solutions for the modern clinical laboratory. 
NPs are being increasingly applied to molecular diagnostics and several technologies are in 
development. NPs, such as gold (Au) NPs or quantum dots (QDs), are the most widely used but 
different other nanotechnology devices, as well as nanobiosensors, are also promising for 
clinical applications. 
 
1.2.3 Imaging 
The development of the effective carrier system does not only mean the execution of the 
delivery, but also the positive confirmation of the site-specific delivery of the drug. Consequently, 
the ability to track and image the fate of any nanomedicine from the systemic to the subcellular 
level becomes essential. NPs can be successfully exploited to improve the utility of fluorescent 
markers for medical imaging and diagnostic purposes.  
Although various fluorescent markers are widely used in research and clinical diagnostic 
applications, current techniques have several disadvantages, such as the requirement of color-
matched lasers, fluorescence bleaching and lack of discriminatory capacity of multiple dyes. 
Fluorescent NPs can greatly overcome these problems, enhancing their use to image tumours 
and other diseases in vivo. 
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1.3 ADVANTAGES OF NANOPARTICLES AS DRUG DELIVERY SYSTEMS 
NPs are colloidal particles with sizes ranging from 10 to 1000 nm in diameter [27,28]. Many 
types of NPs can be formulated from diverse materials with the aim to serve as a possible drug 
delivery vehicle to treat a particular disease.  
Drugs can be loaded onto NPs by various methods, such as encapsulation, surface attachment 
or entrapment [29]. NPs, due to their small size, can efficiently penetrate across barriers 
through small capillaries into individual cells, thus allowing efficient drug accumulation at target 
site. Therefore, the unwanted side effects and the toxicity of the therapeutic agent are reduced 
and the therapeutic efficacy is enhanced [30].  
NPs in pharmaceutical and biotechnological sectors are useful for improving the therapeutic 
index of drugs and provide solutions to future delivery problems for new and upcoming classes 
of biotechnological products, such as recombinant proteins and oligonucleotides. 
Various advantages can be ascribed to NPs: 
- Increase of the aqueous solubility of the drug; 
- Drug protection from degradation; 
- Improvement of drug bioavailability; 
- Production of a prolonged release; 
- Provision of a targeted delivery of the drug; 
- Decrement of drug toxic effects; 
- Possibility of an appropriate form for all routes of administration; 
- Rapid formulation development. 
Thanks to these advantages, NPs can be used to deliver the active therapeutics to the site of 
action. However, despite widespread applications of these NPs, colloid stability has received 
little attention. To improve the stability of NPs, polymeric surfactants or other modifiers are often 
adsorbed or grafted to particles, forming a layer that generates an effective repulsive force 
between NPs that prevents flocculation. 
Concerning the choice of a drug formulation, it should be remembered that no delivery system 
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per se meets all desired requirements for overall/general problem solution. Moreover, optimal 
formulations have to be chosen carefully for each drug, according to the feature of the 
nanocarriers. The aim is to achieve desired drug release profiles in vivo by minimizing side 
effects. 
Concerning the materials used for the production, a possible classification of NPs is between 
non-lipid and lipid-based nanocarriers. Next paragraphs are dedicated to an analysis of these 
different systems. 
 
 
1.4 NON-LIPID COLLOIDAL DRUG CARRIER SYSTEMS 
1.4.1 Polymeric NPs 
Polymeric NPs are nanoparticles prepared from polymers. Depending on the desired properties 
different types of polymers, in term of chain length, type and number can be used.  
Polymers suitable for the preparation of nanoparticles include cellulose derivatives, 
poly(alkylcyanoacrylates), poly(methylidene malonate), polyorthoesters, polyanhydrides and 
polyesters such as poly(lactid acid), poly(glycolic acid) and poly (ε-caprolactone) and their 
copolymers [4]. Various procedures can be applied, such as the coacervation technique, the 
solvent evaporation [31] and solvent diffusion methods, the interfacial polymerization [32], the 
denaturation or desolvation of natural proteins or carbohydrates [32], and the degradation by 
high-shear forces (i.e. by high pressure homogenization [33] or by micro fluidization [34]).  
Colloidal particles are either left as aqueous dispersion or they are converted into solid form, 
usually by lyophilisation [35]. 
They also exhibit a good potential for surface modification and functionalization with different 
ligands, moreover they provide excellent pharmacokinetic control and are suitable to 
encapsulate and deliver a plethora of therapeutic agents. Depending on the type of process 
used for their preparation, these can be NPs, nanospheres or nanocapsules (Fig. 2). 
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Figure 2. Schematic representation of nanospheres and nanocapsules. 
 
Nanospheres have a matrix-like structure where active compounds can be firmly adsorbed at 
their surface, entrapped or dissolved in the matrix. Nanocapsules have a polymeric shell and an 
inner core. In that case, an active substance is usually dissolved in the core but can also be 
adsorbed at their surface [27,36]. The drug is dissolved, entrapped, encapsulated or attached to 
a nanoparticle.  
The main advantage of using NPs for drug-delivery applications is their small size when taken 
up by cells, which could allow efficient drug accumulation at the target sites [37]. Biodegradable 
materials used for the formulation of NPs allow sustained drug release within the target site over 
a period of days or even weeks. Biodegradable NPs formulated from poly D, L-lactide co-
glycolide (PLGA) and polylactide (PLA) have been investigated for sustained drug delivery 
[36,38]. 
The main interest of the researchers is to study their intracellular trafficking and determine the 
parameters that are critical to their efficient cellular uptake and retention. Recently, studies have 
demonstrated rapid escape of NPs from the endo-lysosomal compartment to the cytoplasmic 
compartment [38].  
Multidrug resistance (MDR) is one of the major causes of treatment failure in cancer therapy, 
which may be attributed to the decreased accumulation of drug in the tumour site together with 
the activity of membrane glycoprotein (P-gp)-dependent accelerated drug efflux [39,40]. The 
performed studies suggest that the use of targeted, antisense agent NPs would be a potential 
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approach to overcome tumour drug resistance [41]. 
Another characteristic of NPs is their ability to deliver drugs to the target sites across biological 
barriers such as the blood-brain barrier (BBB) [42,43]. The brain delivery of a wide variety of 
drugs, such as antineoplastic and anti-HIV drugs, is markedly hindered because they have 
great difficulty in crossing the BBB [44]. Thus, by using the nanotechnological approaches, 
researchers have tried to improve the pharmacokinetics of drugs for the treatment of central 
nervous system (CNS) diseases. The application of NPs to brain delivery is a promising way to 
overcome this barrier. Although not fully elucidated, the most likely transport mechanism for 
these particles is via endocytosis across the endothelial cell lining of the BBB. Moreover, by 
packaging therapeutic molecules inside a liposome and decorating the surface of the liposome 
using molecular “Trojan horse” technology, researchers have obtained promising results [45].  
Recently many surface-modified NPs have been used to treat various diseases. Surface 
modification of PLGA NPs with polyethyleneimine (PEI) utilizing a cetyl-derivative was used to 
improve surface functionalization and aid siRNA delivery [46]. 
 
1.4.2 Ceramic NPs 
The use of inorganic (ceramic) particles for drug delivery, especially biomacromolecular 
therapeutics, is emerging as a new area [47], because of their ultra-low size (less than 50 nm) 
and porous nature. It is well documented that smaller-sized drug-carrier systems are more 
effective in evading the uptake by the RES [48]. Silica and other materials such as alumina, 
titania, etc., which are highly compatible with biological systems because of their inert nature, 
are widely being used for the formulation of NPs [49,50]. 
 
1.4.3 Magnetic NPs 
Magnetic NPs (MNPs) are a class of nanoparticle that can be manipulated using magnetic field. 
Such particles commonly consist of magnetic elements such as iron, nickel and cobalt and their 
chemical compounds. 
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MNPs are increasingly being being widely used for biotechnological and biomedical applications. 
Drug delivery may be benefited by the use of MNPs because these particles can be addressed 
to a specific site, such as a tumour, thereby reducing the systemic distribution of cytotoxic 
compounds in vivo, result in effective treatment at lower doses [51]. 
 
1.4.4 Metal-based NPs 
Metal NPs can be synthesized in extremely small sizes of around 50 nm and thus the large 
surface area provides the ability to carry a relatively higher dose of drugs.  
AuNPs are the most commonly used as they offer manifest advantages. It is easy to synthesize 
a range of sizes of Au NPs by changing few parameters by simple, cheap and reliable methods. 
Other common metal-based NPs are silver NPs and amphiphilic TiO2 nanotube. 
Silver NPs have wound-healing properties improving cosmetic appearance in a dose-dependent 
manner after topical delivery. These NPs also exert positive effects through their antimicrobial 
properties, reduction in wound inflammation and modulation of fibrogenic cytokines [52]. 
Amphiphilic TiO2 nanotube arrays can serve as an actively controllable drug delivery system by 
utilising the photocatalytic ability of TiO2 [53]. 
 
1.4.5 Polymeric micelles 
Polymeric micelles represent a class of colloidal system formed of block copolymers consisting 
of hydrophilic and hydrophobic monomer units [54]. These micelles are composed of a core of 
hydrophobic blocks stabilized by a corona of hydrophilic polymeric chains. Although a variety of 
hydrophilic polymers can be used, in majority of cases, PEG blocks with a molecular weight 
ranging from 1 to 15 kDa are used as corona-forming blocks and the length of a hydrophobic 
core-forming block is close or somewhat lower than that of a hydrophilic block. Enhancing 
drugs' solubility using micelle-forming surfactants results in increased water solubility of a poorly 
soluble drug. They also improve drugs' bioavailability by enhancing their permeability across 
physiological barriers. Thus, they bring about substantial changes in drug biodistribution. 
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1.4.6 Dendrimers 
Dendrimers derive their name from the Greek word “dendra”, meaning reminiscent of a tree. 
They are polymeric molecules composed of multiple perfectly branched monomers that 
emanate radially from a central core. Though many biological applications use dendrimers 
based on polymers, such as polyamidoamines (PAMAMs), polyamines, polyamides 
(polypeptides), poly (aryl ethers), polyesters, carbohydrates and DNA, in most cases PAMAM 
dendrimers are used [55,56]. 
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1.5 LIPID-BASED NANOSYSTEMS 
Although within the remit of the above mentioned nanoscience initiatives, lipid-based 
nanosystems such as nanoemulsions, lipid-core micelles, small unilamellar vesicles, solid lipid 
nanoparticles, nanostructured lipid carriers, colloidal liquid crystalline structures, cubosomes 
and variations thereof, have long been in existence and some have long been improving 
patient's lives. Indeed, lipid-based nano-formulations are among the most attractive candidates 
for improving drug solubility and for site-specific targeting following parenteral administration. 
In recent years, a particular attention has been focused on new generations of lipid 
nanoparticles such as nanostructured lipid carriers and monoolein aqueous dispersions, derived 
from the mesophases originated from the system monoolein/water/poloxamer. These 
nanoparticles have been analysed as possible drug delivery systems and are the object of the 
discussion of this doctorate project. 
 
1.5.1 Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) 
Solid lipid NPs (SLN) are a colloidal carrier system for controlled drug delivery developed at the 
beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric 
NPs [12]. These particles are delivery systems where the nanodispersed phase has a solid 
matrix of crystalline solid lipids (i.e. lipids solid both at room and at body temperature) and is 
stabilized by surfactant(s). SLN can be formulated by using highly purified triglycerides, complex 
glyceride mixtures or even waxes.  
In comparison with other particulate carriers, SLN have many advantages for drug delivery, 
such as good tolerability, biodegradability [57], a high bioavailability by ocular administration 
[58] and a targeting effect on the brain [59]. SLN have been developed and investigated for 
parenteral, pulmonary and dermal application routes [60-62].  
In recent years, the study of SLN has markedly increased, especially with the method of high 
pressure homogenization.  
Because of their small sizes, SLN may be injected intravenously and used to target drugs to 
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particular organs. The particles, together with all intravenously injected and colloidal particulates, 
are cleared from the circulation by the liver and spleen. In tumour tissues, drugs can be targeted 
by PEG-coated polymeric NPs (stealth NPs) that helps in escaping from reticuloendothelial 
system (RES) [63]. This effect may be also achieved using block polyoxyethylene polypropylene 
copolymers like Pluronic F188 in which the hydrophobic portion of the molecule forms the NP 
matrix while the water soluble polyoxyethylene block forms a hydrophilic coating on the particle. 
Stealth SLN increases the tumour accumulation, antibacterial activity of antiparasitic and 
antifungal drugs, and allows brain delivery of anticancer drugs not capable of crossing the BBB 
[64]. 
Clear advantages of SLN include the use of physiological well tolerable lipids [65], the 
avoidance of organic solvents in some preparation processes, a wide potential application 
routes (dermal, oral, intravenous) and the rapid and effective preparation process allowing the 
possibility of large scale production [66]. 
Common disadvantages of SLN include particle aggregation, particle growth, unpredictable 
gelation tendency, unexpected dynamics of polymorphic transition, burst drug release and 
consequently low incorporation capacities due to the crystalline structure of the solid lipid 
[3,67,68]. 
This last mentioned drawback can be explained by the crystallization process to which SLN are 
subjected during the cooling process, causing a transition of lipids in higher energy modification 
α and β’. Triglycerides are known to crystallize mainly in three polymorphic forms which 
transform monotrophically from α via β′ to β [69].  
During storage, SLN triglycerides are subjected to a shift into the low energy and more ordered 
β modification. The formed high degree of order causes a reduction of imperfections in the 
crystal lattice and consequently, the drug expulsion (Fig. 3). 
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Figure 3. Mechanism of drug expulsion during storage of SLN dispersions; transition to highly ordered lipid crystal 
[15] 
 
To obtain a sufficiently high drug load, the creation of a less ordered solid lipid matrix is 
necessary. In this case, the drug can dispose itself between the chains of the fatty acids or 
between the lipid layers and the imperfections. When SLN are formulated with mono acid highly 
purified glyceride, such as Tristearin, the drug loading is limited and very frequently drug 
expulsion occurs within hours or few days due to the formation of the perfect β modification [70].  
The second generation of SLN, avoiding some disadvantages of classic SLN, is represented by 
Nanostructured Lipid Carriers (NLC), which are composed of a solid lipid matrix with a certain 
content of a liquid lipid phase [71].  
Liquid lipids are able to better disperse lipophilic drugs than solid lipids. The liquid lipids form 
droplets within the solid lipid particles matrix, providing a high incorporation capacity and a 
control of drug release (Fig 4). 
 
 
Figure 4. Perfect crystal in SLN comparable with a brick wall and structure with imperfections due to spacially very 
different molecules in NLC [15] 
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The use of different lipid molecules (solid and liquid at room temperature) in the preparation of 
NLC allow the building of the matrix of the wall with different types of stones leaving enough 
imperfections to accommodate the drugs. In this way the problem of the formation of a perfect 
crystal, that seems a wall made of bricks, is overcome. 
Especially, as schematized in figure 5, three types of NLC can be produced: 
1. Imperfect type 
2. Amorphous type 
3. Multiple type 
 
 
 
Figure 5. Different types of NLC compared to the ordered matrix of SLN (A); NLC types: imperfect type (B), 
amorphous type (C), multiple type (D) [15] 
 
The process of drug loading in SLN is due to the formation of lipid crystals. The formation of a 
perfect crystal causes drug expulsion. Thus, by avoiding crystallization and creating more 
imperfections in the crystal the drug loading is higher (Fig 5A). 
NLC are solid but not crystalline particles. By using special mixtures of solid lipids and liquid 
lipids (e.g. isopropylmyristate, hydroxyloctacosanylhydroxylstearate) the obtained nanoparticles 
become solid after cooling but they don’t crystallize (Fig. 5C).  
A B 
C D 
		
1. Introduction 
	
	 	
17
From the production point of view, a too high concentration of drug in the molten lipidic phase 
could lead to an immediate drug expulsion during the cooling process or create a dilution in the 
cold water. Based on these supposes, the multiple type of NLC was developed (Fig. 5D). 
In this last structure, the solid matrix of the lipid nanoparticle contains tiny liquid nano-
compartments of oil, in which the drug solubility is higher. It follows an increase in the total drug 
loading capacity. The oil nano-compartments are all surrounded by solid matrix, allowing, also 
in this case, a prolonged drug release. 
 
1.5.2 Monoolein aqueous dispersions (MAD) 
Surfactants, lipids and polymer molecules that have both polar and nonpolar components are 
called amphiphilic. The hydrophobic effect drives amphiphilic molecules into polar solvents to 
spontaneously self-assemble into a rich array to thermodynamically stable lyotropic liquid 
crystalline phases with characteristic lengths on the nanometer scale. 
The content of water or other solvent molecules changes the self-assembled structures.  
A generic progression of phases, going from low to high amphiphile concentration, is: 
1. Discontinuous cubic phase (micellar cubic phase) 
2. Hexagonal phase (hexagonal columnar phase) (middle phase) 
3. Lamellar phase 
4. Bicontinuous cubic phase 
5. Reverse hexagonal columnar phase 
6. Inverse cubic phase (Inverse micellar phase) 
At very low amphiphile concentration, the molecules will be dispersed randomly without any 
ordering. At slightly higher (but still low) concentration, amphiphilic molecules will spontaneously 
assemble into micelles or vesicles. This is done so as to 'hide' the hydrophobic tail of the 
amphiphile inside the micelle core, exposing a hydrophilic (water-soluble) surface to aqueous 
solution. These spherical objects do not order themselves in solution and are denoted by the 
symbol I1. This is a highly viscous, optically isotropic phase in which the micelles are arranges 
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on a cubic lattice.  
At higher amphiphile concentrations the micelles fuse to form cylindrical aggregates of indefinite 
length, and these cylinders are arranged on a long-ranged hexagonal lattice. This lyotropic 
liquid crystalline phase is known as the 'hexagonal phase', or more specifically the 'normal 
topology' hexagonal phase and is generally denoted by the symbol HI.  
At higher concentrations of amphiphile the 'lamellar phase' is formed. This phase is denoted by 
the symbol Lα and consists of amphiphilic molecules arranged in bilayer sheets separated by 
layers of water. Each bilayer is a prototype of the arrangement of lipids in cell membranes. For 
most amphiphiles that consist of a single hydrocarbon chain, one or more phases having 
complex architectures are formed at concentrations that are intermediate between those 
required to form a hexagonal phase and those that lead to the formation of a lamellar phase. 
Often this intermediate phase is a bicontinuous cubic phase (Fig. 6). 
 
 
 
 
Figure 6. Schematic showing the aggregation of amphiphiles into micelles and then into lyotropic liquid crystalline 
phases as a function of amphiphile concentration and of temperature. 
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The lamellar phase is the basis of the planar lipid bilayer of the vesicle structure, while the 
bicontinuous phase consists of a single continuous curved bilayer that forms a complex network 
with 3D cubic symmetry and continuous water channels. Cubic phase surface could assume 
different curvatures: Ia3d (gyroid surface, G), Pn3m (diamond surface, D), lm3m (primitive 
surface, P) [72] (Fig. 7). 
 
 
 
Fig.7 Cubic phase surface curvatures. Individual lipids are shown as small circles with adjoined curved lines, representing the polar 
headgroup and hydrophobic acyl chain respectively. The red and green regions represent water. [72] 
 
 
Monoglycerides are polar lipids with poor water solubility that exhibit aqueous phase behaviour, 
reflecting their structural similarity to nonionic surfactants. The most studied, among aqueous 
monoglycerides systems, is that formed by monoolein, the unsaturated C18 monoglyceride. 
As shown in figure 6, the formation of cubic phases is often localized in a narrow region 
between lamellar and hexagonal liquid crystalline phases. Differently, the monoolein-water 
system is the only that possesses a cubic phase region spanning large compositional and 
temperature ranges (Fig. 8). 
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Fig.8 Aqueous phase behaviour of the monoolein-water system, evidencing the existence of two cubic phases [73]. 
 
 
In the cubic phase, the minimal surface is formed by the self assembled bilayer that occurs as 
the hydrophobic or hydrophilic portions of the surfactants molecules line up to minimize their 
interaction with their opposite. The three structures, P-, D- and G- surfaces, are all bicontinuous 
(i.e., they divide space into two continuous but nonintersecting regions); in the case of cubic 
phases, two separate regions of hydrophilic material (water channels) are formed. 
Cubic liquid crystals are transparent, isotropic viscous phases and physically stable in excess 
water [74-77]. Since cubic phases are characterized by high viscosity, they are difficult to 
administrate by parenteral routes. For this reason some researchers have developed the 
emulsification of cubic lipid phases in water resulting in the production of cubosomes that can 
be defined as nanoparticulate disperse systems characterized by high biocompatibility and 
bioadhesivity [78,79]. 
Dispersed particles of bicontinuous cubic phases were first observed during studies of fat 
digestion that simulated stomach contents by combining oil with lipase and bile salts [80]. 
One of the first published instances of the word “cubosomes” appears in a review written by 
Larsson [81] in which the author discussed about implications of bicontinuous cubic phases to 
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biological membranes. Cubosomes structures, such as bulk cubic phases, are critical elements 
of some biological processes and for example, occur naturally in bacterial cells [82]. 
The formation of cubosomes is possible in binary and ternary systems with a sufficiently large 
miscibility gap between the cubic phase and the solvent. Colloidal stabilization of cubosomes is 
good when Poloxamer 407 is used to provide steric stabilization against aggregation and 
coalescence, but other suitable polymers can be used as well [83]. 
Concerning their applications in pharmaceutical and biotechnological fields, cubosomes have 
been proposed as a delivery system able to provide both a solubilization benefit (increased drug 
payload) and a system for controlled or sustained release [84]. In particular, cubosomes show 
the ability to solubilize hydrophobic, hydrophilic and amphiphilic molecules (Fig. 9) and a high 
biodegradability by simple enzyme action [85]. 
 
 
 
Fig.9 Cubosome exhibiting its cavernous internal and cubic structure and its membrane composition with different 
drug-loading modalities. 
 
 
Compared to liposomes or vesicles, cubosomes possess much higher bilayer area-to-particle 
volume ratios as well as higher viscous resistance to rupture [84]. Because of their properties, 
these versatile delivery systems can be administrable by different routes (such as orally, 
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parenterally, or percutaneously) [86]. 
The methods of preparation [87,88] and the inner structure [89,90] of cubosomes have been 
widely studied. Nevertheless, drug release from these systems has been poorly investigated 
[91].  
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1.6 AIMS AND ORGANIZATION OF THE THESIS 
In recent years, the field of lipid nanostructures shows a growing interest from the 
pharmaceutical technology research groups world wide. In particular, Solid Lipid Nanoparticles 
(SLN), Nanostructured Lipid Carriers (NLC) and Monoolein Aqueous Dispersions (MAD) have 
been proposed as new carrier systems for many applications. 
 
In this thesis different NLC, SLN or MAD formulations were developed as drug delivery systems 
specifically for antiparkinson or antimycotic drugs, in order to prolong their action and reduce 
the side effects. The thesis consists of seven main chapters. 
 
The first chapter contains an introduction on nanoparticulate systems, focusing the attention on 
properties and the differences existing between non-lipid and lipid vectors. 
 
The second and third chapters describe materials and methods used in this work respectively. 
 
From chapter four to six, the applications of lipidic nanosystems as delivery vectors are 
analysed in order to improve the bioavailability and controlled release of incorporated drugs. 
 
In chapter four, NLC and MAD formulations containing Bromocriptine are described and 
compared. In particular, characterization of morphology, size, inner structure and drug 
distribution of nanosystems have been made. Finally, in vitro and in vivo analyses have been 
performed. 
 
In chapter five, four different new L-dopa derivatives are studied as model drugs for NLC and 
SLN formulations. After the inclusion in nanoparticulate systems, the derivatives have been 
analysed in dimensions, morphology, L-dopa release by time and in vitro release tests.  
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In chapter six, NLC and MAD are described as possible drug delivery systems for Clotrimazole, 
an antimycotic agent. After dimensional, morphology and stability studies, NLC and MAD have 
been viscosized in order to facilitate a mucosal application and delivery of the drug. The 
obtained gels have been analysed through rheological and calorimetric assays, then cytotoxic 
and anticandidal activities have been tested. 
 
The last chapter contains the conclusions of the work considering the obtained results. 
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2. MATERIALS 
 
The materials used in this work are only partially composed of individual chemical substances 
and their composition may differ according to the manufacturer. Therefore, the physicochemical 
properties and the producer details for all the materials used are given in the present section. 
 
 
2.1 SOLID LIPIDS 
Lipids that are solid at room temperature are saturated. The solid lipids used in this work are 
well tolerated, accepted for human use and they are characterized by in vivo biodegradability. 
 
2.1.1 Tristearin 
Tristearin is also known as glycerol tristearate, stearin, glyceryl tristearate, trioctadecanoin, 
hardened oil, stearin, tri-, spezialfett 118, stearic triglyceride. 
His molecular formula is C57H110O6 and his molecular weight is 891.4797.	
Tristearin is the primary fat in beef. It is a triglyceride, a molecule of glycerine has reacted with 
three molecules of the fatty acid stearic acid. It is a saturated fat, solid at room temperature. 
Tristearin was provided by Fluka (Buchs, Switzerland). 
 
 
2.2 LIQUID LIPIDS (OILS) 
Liquid lipids at room temperature are unsaturated. The oils used in this work are well tolerated 
and accepted for human use. 
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2.2.1 Miglyol	® 812 
It is a liquid lipid at room temperature, having a density between 0.945 and 955 g/cm3. This oil 
consists of medium chain triacylglycerols (C8-C10) (caprylic/capric triglycerides) and it is 
virtually colourless and of neutral odour and taste. It is used as skin oil and as dissolution 
medium for many substances. It is soluble in hexane, toluene, diethyl ether, ethyl acetate, 
acetone, isopropanol and ethanol 96%. It is miscible in all ratios with paraffin hydrocarbons and 
natural oils. The acid value is 0.1 mg KOH/g and the saponification value is between 325-345 
mg KOH/g [92]. 
Miglyol 812 was purchased from Eigenmann & Veronelli (Rho, Milano, Italy).  
 
2.2.2 Monoolein 
Synonyms of monoolein are RYLO MG 19, Arlacel™ 186, D-L-alpha-monoolein, delta 9 cis 
monoolein, glycerol-1-monooleate, glycerol alpha-monooleate, glycerol monooleate, glyceryl 
monooleate, glyceryl cis-9-octadecenoate. His molecular formula is C21H40O4 and his molecular 
weight is 356.54. 
Monoolein is a monoacylglycerol with 9-cis-octadecenoic acid at the sn-1 position of glycerol. 
The mesophase propensities and structure of monoolein dispersed in water are of interest in a 
number of areas ranging from controlled uptake and release to cosmetic, food and 
pharmaceutical formulations. 
RYLO MG 19 was purchased from Danisco Cultor (Grindsted, Denmark). 
 
 
2.3 EMULSIFYING AGENTS 
The International Union of Pure and Applied Chemistry (IUPAC) defines the properties of an 
emulsifying agent as a surfactant, which is positively adsorbed at interfaces and lowers the 
interfacial tension [93]. Surfactants have amphiphilic structures and are able to form micelles. 
Some polymers (i.e. poloxamers) can function in the same manner, if they have a sufficient 
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surface activity. 
 
2.3.1 Pluronic F68 
Lutrol F 68, (oxirane, methyl-, polymer with oxirane (75;30)) or poloxamer 188 is a water-soluble 
non-ionic polyoxyethylene-polyoxypropylene polymer. Its value in the HLB system (Hydrophile - 
Lipophile Balance) amounts to 29. The stabilizer and solution enhancer does not cause toxic 
reactions after parenteral, dermal or peroral administration [92]. Moreover, the transition time of 
gut is not influenced in GIT of rats [92]. Tenside micelles are not likely to occur in the 
concentration range of poloxamer used in this study. 
Poloxamer 188 arranges only at higher concentrations and temperatures in form of micellar 
structures [94,95]. 
Lutrol F 68, was a purchased from BASF ChemTrade GmbH (Burgbernheim, Germany). 
 
2.3.2 Pluronic F127 
Pluronic F127 (PEO98-POP67-PEO98) or poloxamer 407, is a hydrophilic non-ionic surfactant of 
the more general class of copolymers known as poloxamers. Poloxamer 407 is a triblock 
copolymer consisting of a central hydrophobic block of polypropylene glycol flanked by two 
hydrophilic blocks of polyethylene glycol. The approximate length of the two PEG blocks is 101 
repeat units while the approximate length of the propylene-glycol block is 56 repeat units. 
Poloxamer 407 shows thermo-reversible properties. Its fluid state at room temperature 
facilitates the administration while its gel state above sol-gel transition temperature promotes 
prolonged release of pharmacological agents. Pharmaceutical evaluation consists in 
determining the rheological behaviour (flow curve or oscillatory studies), sol-gel transition 
temperature, in vitro drug release using either synthetic or physiological membrane and 
(bio)adhesion characteristics. Poloxamer 407 formulations led to enhanced solubilisation of 
poorly water-soluble drugs and prolonged release profile for many galenic applications (e.g., 
oral, rectal, topical, ophthalmic, nasal and injectable preparations) but did not clearly show 
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relevant advantages when used alone. Combination with other excipients like poloxamer 188 or 
mucoadhesive polymers (i.e. xanthan gum, sodium alginate, methyl cellulose and others) 
promotes poloxamer 407 action by optimising sol-gel transition temperature or increasing 
bioadhesive properties. Inclusion of liposomes or micro(nano)particles in poloxamer 407 
formulations offers interesting prospects, as well [96].  
Pluronic F127 was obtained from BASF (Ludwigshafen, Germany).  
 
2.3.3 Soybean phosphatidylcholine 
Phosphatidylcholine (PC) is a phospholipid that incorporates choline as a head group. 
Phosphatidylcholine is a major constituent of cell membranes and is more commonly found in 
the exoplasmic or outer leaflet of a cell membrane. It is thought to be transported between 
membranes within the cell by phosphatidylcholine transfer protein (PCTP) [97]. 
Phosphatidylcholines are composed of a choline head group and glycerophosphoric acid with a 
variety of fatty acids, one being a saturated fatty acids and one being an unsaturated fatty acid. 
The phospholipids are such a major component of lecithin that in some contexts the terms are 
sometimes used as synonyms. However, lecithin extract consists of a mixture of 
phosphatidylcholine and other compounds. 
In pharmaceutical applications it acts as a wetting and stabilizing agent, it helps in 
emulsifications and encapsulation and it is a good dispersing agent. It can be used in 
manufacture of intravenous fat infusions and for therapeutic use. 
Phospholipon® 90G (P 90G) is a highly purified soybean lecithin that contains at least 90% 
phosphatidylcholine. P 90G was supplied by Rhône-Poulenc-Rorer (Germany). 
 
2.3.4 Labrasol 
Labrasol	 ® or caprylocaproyl macrogol-8 glycerides is a non-ionic water dispersible surfactant 
composed of well-characterised polyethylene glycol (PEG) esters, a small glyceride fraction and 
free PEG. 
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It is able to self-emulsify on contact with aqueous media forming a fine dispersion or to act as 
solubilizer and wetting agent. It is also used as bioavailability enhancer. 
It is obtained from coconut oil and has very low toxicity with an LD50 of 22g/kg for rats. 
Labrasol® was purchased form Gattefossé (France). 
 
 
2.4 WATER 
The water used in all experiments was purified water by reverse osmosis and was obtained 
from a Milli Q Plus system (Millipore®, USA). 
 
 
2.5 OTHER MATERIALS 
FL-70 was used for SdFFF analyses. FL-70 is a detergent composed of water 88.8%, 
triethanolamine oleate 3.8%, sodium carbonate 2.7%, Alcohols, C12-14-secondary, ethoxylated 
1.8%, Tetrasodium ethylenediaminetetraacetate 1.4%, Polyethylene glycol 0.9%, Sodium oleate 
0.5%, Sodium bicarbonate 0.1%.  
FL-70 was obtained from Fisher Scientific (Fair Lawn, NJ, USA).  
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2.6 DRUGS 
 
2.6.1 Bromocriptine 
 
 
Figure 10. Chemical structure of Bromocriptine. 
 
Bromocriptine (Fig. 10), an ergoline derivative, is a dopamine agonist that is used in the 
treatment of pituitary tumours, Parkinson’s disease (PD), hyperprolactinemia, neuroleptic 
malignant syndrome and type 2 diabetes. 
Bromocriptine is a dopamine receptor agonist, which activates postsynaptic dopamine receptors. 
The dopaminergic neurons in the tubero-infundibular process modulate the secretion of 
prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be 
dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor 
function. Clinically, Bromocriptine significantly reduces plasma levels of prolactin in patients with 
physiologically elevated prolactin as well as in patients with hyperprolactinemia. The inhibition of 
physiological lactation as well as galactorrhea in pathological hyperprolactinemic states is 
obtained at dose levels that do not affect secretion of other tropic hormones from the anterior 
pituitary. Experiments have demonstrated that Bromocriptine induces long lasting stereotyped 
behaviour in rodents and turning behaviour in rats having unilateral lesions in the substantia 
nigra. These actions, characteristic of those produced by dopamine, are inhibited by dopamine 
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antagonists and suggest a direct action of Bromocriptine on striatal dopamine receptors. 
Bromocriptine is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in 
humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, 
where it lowers elevated blood levels of growth hormone in the majority of patients. 
In about 75% of cases of amenorrhea and galactorrhea, Bromocriptine therapy suppresses the 
galactorrhea completely, or almost completely, and reinitiates normal ovulatory menstrual 
cycles. 
Galactorrhea may take longer to control depending on the degree of stimulation of the 
mammary tissue prior to therapy. At least a 75% reduction in secretion is usually observed after 
8-12 weeks. Some patients may fail to respond even after 12 months of therapy. 
In many acromegalic patients, Bromocriptine produces a prompt and sustained reduction in 
circulating levels of serum growth hormone. 
Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical 
condition characterized by a progressive deficiency in dopamine synthesis in the substantia 
nigra, by directly stimulating the dopamine receptors in the corpus striatum. 
The pharmacokinetics and metabolism of Bromocriptine in human subjects were studied with 
the help of radioactively labelled drug. Twenty-eight percent of an oral dose was absorbed from 
the gastrointestinal tract. The blood levels following a 2.5 mg dose were in the range of 2-3 ng 
equivalents/mL. Plasma levels were in the range of 4-6 ng equivalents/mL indicating that the 
red blood cells did not contain appreciable amounts of drug and/or metabolites. In vitro 
experiments showed that the drug was 90%-96% bound to serum albumin. 
Bromocriptine was completely metabolized prior to excretion. The major route of excretion of 
absorbed drug was via the bile. Only 2.5%-5.5% of the dose was excreted in the urine. Almost 
all (84.6%) of the administered dose was excreted in the faeces in 120 hours. 
Bromocriptine mesylate, 2-Bromo--ergocriptine methansulfonate salt (BC), amphetamine and 
6-hydroxydopamine (6-OHDA) were purchased from Sigma Chemical Company (St Louis, MO, 
USA). 
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2.6.2 L-DOPA derivatives 
L-Dopa (LD) is a direct precursor of dopamine (DA), which is deficient in the brains of patients 
suffering from Parkinson's disease (PD). Although LD is the treatment of choice, its metabolism 
generates a variety of free radicals that contribute to the progression of the disease, increasing 
the loss of nigrostriatal dopaminergic neurons [98]. In particular, it was demonstrated that 
systemic administration of LD in the rat increases the production of free radicals in the 
substantia nigra [99]; in addition, cell-death, both of the necrotic and the apoptotic types, was 
observed in neuronal and non-neuronal cell cultures treated with LD [100]. 
Experimental studies have also shown that LD alters cellular energy metabolism, probably by 
inducing oxidative damage of specific enzymes of the mitochondrial respiratory chain [101]. 
Miller et al. confirmed that catecholamines, including the neurotransmitter DA and its 
biochemical precursor LD, are subjected to autoxidation [102]. This process, which is 
accelerated in the presence of pro-oxidative transition metals, such as iron and copper, is 
enhanced by the presence of neuromelanin in dopaminergic neurons, due to its reported ability 
to accumulate iron and consequently acting through promotion of Fenton and Haber-Weiss 
reactions with production of potentially cytotoxic reactive oxygen species (ROS) [103]. 
These ROS have been hypothesized to play a role in the progressive and selective loss of 
nigrostriatal dopaminergic neurons that occurs in aging and in neurodegenerative disorders 
such as PD and Alzheimer disease [104]. This hypothesis suggests that inhibition of 
catecholamine autoxidation and the scavenging of ROS produced by such oxidation are 
important strategies for preventing or slowing down the progression of aging and aged-related 
neurodegenerative disorders. It is well known that low molecular weight natural free radical 
scavengers such as glutathione, vitamin E, carnosine and ascorbic acid have been extensively 
studied as useful neuroprotective agents [105,106]. 
However, the use of these natural antioxidants as therapeutic agents is limited, mainly due to 
the marginal efficiency of these scavengers to cross the blood-brain barrier. Conversely, 
antioxidant (e.g. ascorbate or R-tocopherol) interventions that do not affect iron accumulation 
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have shown only limited efficacy in lowering oxidant stress in the aging brain [107,108]. Thus 
new, nontoxic, therapeutic agents that improve both alterations in iron and antioxidant status 
may be needed. 
Starting from these data, the synthetic study, performed by Professor Di Stefano group at the 
University of Chieti, was focused on providing molecular combinations obtained joining an 
antioxidant molecule with a therapeutic compound also able to generate a targeted antioxidant. 
These compounds could permit a targeted delivery of the antioxidant moiety directly to specific 
groups of cells, including neurons, where cellular stress is associated with pathology, including 
that associated with normal aging and neurodegenerative disorders [109]. With regard to PD, an 
analysis of the literature reveals that despite antioxidant therapy having been explored in a 
number of pathological conditions, the joining of an antioxidant molecule to a group capable of 
targeting a specific population of dying cells has not so far been considered. 
In addition, another strategy adopted for the production of prodrug forms was the synthesis of 
dimeric derivatives, in which two identical structural molecules are linked together through a 
spacer and after administration are metabolized into their identical agents [110-113]. 
 
Derivative A (Der-A) 
Der-A (Fig. 11) was synthesized through the interaction of 3,4-diacetyloxy-L-dopa methyl ester 
hydrochloride 3 with caffeic acid 4 [114-116]. Preliminary in vitro and in vivo studies evaluated 
chemical and enzymatic properties of this molecule and showed that Der-A is stable in aqueous 
solutions and improves the release of LD and dopamine in the brain [117].  
 
 
 
 
Figure 11. Chemical structure of Der-A. 
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Derivatives B (Der-B) and C (Der-C) 
For the synthesis of Der-B and Der-C novel molecular combinations were proposed in which 
dopamine is linked to antioxidant and iron-chelating agents such as (R)-R-Lipoic acid. 
These multifunctional codrugs, containing antioxidant molecules whose benefits have been 
demonstrated in several neurodegenerative disorders, could represent useful dopaminergic 
agents devoid of the pro-oxidant effects associated with the presence of the catecholic moiety 
[118]. 
The amides were synthesized by the classical methods through the interaction of (R)-R-lipoic 
acid with 2-(3,4-diacetoxy)-phenylethylamine (Fig. 12), and 2-(3,4- dihydroxy)-phenylethylamine 
(Fig. 13), respectively. 
 
 
 
Figure 12. Chemical structure of Der-B. 
 
 
 
Figure 13. Chemical structure of Der-C. 
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Derivative D (Der-D) 
Der-D (Fig. 14) was synthetized protecting all the three sensitive centres of LD (the carboxy 
function, the amino group and the catechol system) and following the classical methods through 
the interaction of 3,4-diacetyloxy-l-phenylalanine methyl ester hydrochloride with the respective 
dicarboxylic acid dichloride [119]. Der-D showed chemical stability in aqueous, acid and 
physiological solutions. Furthermore, in vitro studies showed a slow release of LD from Der-D in 
human and rat plasma. 
 
 
Figure 14. Chemical structure of Der-D. 
 
The physico-chemical characteristics of LD derivatives are reported in table I. 
 
 
Table I. Physico-chemical characteristics of LD derivatives. 
 Molecular weight Melting point (°C) λ (nm) Colour 
Der-A 429.202 140  254 Yellow ochre 
Der-B 341.332 80 282 Grey 
Der-C 397.399 60 220 Yellow phosphorescent 
Der-D 630.307 170 220 Grey/White 
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2.6.3 Clotrimazole 
Clotrimazole (Fig. 15), an imidazole derivative, is an antifungal agent commonly used in the 
treatment of fungal infections (of both humans and other animals) such as vaginal yeast 
infections, oral thrush and ringworm. 
It is commonly available as an over-the-counter substance in various dosage forms, such as a 
cream, and also (especially in the case of ear infection) as a combination medicine. It is also 
available as a troche or throat lozenge. Fungal infections can be slow to clear up, so the usual 
course for an anti-fungal agent is, in general, longer than the typical 3–7 days of an antibiotic.  
Additionally, Clotrimazole is used to treat the sickling of cells (related to sickle cell anaemia) by 
blocking ion channels in the RBC (red blood cell) membrane, keeping ions and water within the 
cell [120,121]. 
The primary mechanism of action of clotrimazole is against the division and growing of fungi 
[122]. Clotrimazole alters the permeability of the fungal cell wall and inhibits the activity of 
enzymes within the cell. Studies show that minimal concentrations of clotrimazole causes 
leakage of intracellular phosphorus compounds into the ambient medium along with the 
breakdown of cellular nucleic acids and an accelerated K+ efflux [122]. This leads eventually to 
the cell's death. It does not appreciably spread through the user's body but remains at the point 
of application [123]. 
Potential for drug interactions with clotrimazole oral exists, as it is a potent, specific inhibitor of 
cytochrome P450 oxidase and may alter the metabolism of other drugs. 
 
 
 
Figure 15. Chemical structure of Clotrimazole.
		
3. Methods 
	
	 	
37
3. METHODS 
 
3.1 NANOSYSTEMS PRODUCTION 
 
3.1.1 NLC preparation 
NLC were alternatively prepared by stirring, followed by homogenization or ultrasonication. 
Briefly, 1 g of lipidic mixture was melted at 70°C. The lipidic mixture concentration ranged 5% 
w/w (with respect to the total weight of dispersions) and was constituted of a mixture 
tristearin/tricaprin 2:1 w/w. The fused lipid phase was dispersed in 19 ml of an aqueous 
poloxamer 188 solution (2.5% w/w) at 13,500 rpm, 70°C for 1 min, using a high-speed stirrer 
(Ultra Turrax T25, IKA-Werke GmbH & Co. KG, Staufen, Germany). The emulsion was 
subjected to ultrasonication (MicrosonTM, Ultrasonic cell Disruptor) at 6.75 kHz for 15 min and 
then cooled down to room temperature by placing it in a water bath at 22 °C. NLC dispersions 
were stored at room temperature. 
In the case of BC-containing dispersions, 5 mg of the drug (0.025% w/w with respect to the total 
dispersions, 0.5% w/w with respect to the lipid phase) were added to the molten lipidic mixture 
and dissolved before adding to the aqueous solution. 
LD derivatives-containing NLC were prepared by adding 5 mg of LD-derivate to the molten 
lipidic mixture and by adding it in the aqueous solution. 
In the case of CLO-containing dispersions, 20 mg of the active were added to the lipid mixture 
and dissolved before addition to the aqueous solution. 
 
3.1.2 SLN preparation 
SLN were prepared by stirring and ultrasonication method, using the same parameters used for 
NLC production. Briefly, 0.8 g of tristearin and 0.005 g of soybean phosphatidylcholine were 
melted at 70°C. The fused lipid phase was added to 0.2 g of Labrasol and the obtained melted 
mixture was dispersed in 19 ml of an aqueous poloxamer 188 solution (2.5% w/w). The 
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emulsion was subjected to ultrasonication (MicrosonTM, Ultrasonic cell Disruptor) at 6.75 kHz for 
15 min and then cooled down to room temperature by mean of a water bath. SLN dispersions 
were stored at room temperature. 
Alternatively 2.5 (1x), 5 (2x) or 10 mg (4x) of Der-A were added to the molten mixture of 
tristearin/soybean phosphatidylcholine/Labrasol, dissolved and added to the aqueous phase.  
 
3.1.3 MAD preparation 
Production of dispersions was based on the emulsification of monoglycerides/surfactant 
mixtures in water. In particular, the monoglyceride-based lipidic phase was composed of RYLO 
MG19.  
Poloxamer 407 was used as surfactant in a concentration of 0.5% wt/wt with respect to the 
disperse phase. The concentration of the monoglyceride/surfactant mixture was 5% wt/wt with 
respect to the total weight of the dispersion. Typically, 2.25 g of RYLO MG19 plus 0.25 g 
poloxamer 407 were melted in a water bath (Haake FS bath, Enco sas, Karlsruhe, Germany). 
The obtained molten mixture was added dropwise into 47.5 mL of water at 70°C under 
mechanical stirring (Eurostar digital stirrer, IKA Labotechnik, Sardo, Torino, Italy) at 1500 rpm. 
The dispersion was maintained under stirring and was cooled to room temperature up to the 
solidification of lipid droplets (after 2 hours). Afterwards, the dispersion was heated to 60°C and 
subjected to homogenization at 13500 rpm (Ultra Turrax, Janke & Kunkel, Ika-Werk, Sardo, 
Italy) for 5 minutes. Then, the dispersion was cooled at room temperature and stored in glass 
vials at 25°C. 
Twelve point five (12.5) mg of BC (0.55% w/w with respect to the monoolein, 0.025% w/w with 
respect to the dispersion) were added to the molten MO/poloxamer solution and dissolved 
before addition to the aqueous solution. 
Conversely, In the case of CLO-containing MAD, 50 mg of the active were added to the molten 
MO/ poloxamer mixture and dissolved before addition to the aqueous solution. 
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3.2 NANOSYSTEMS CHARACTERIZATION 
 
3.2.1 Water and dispersed phase loss after NLC and MAD production 
The disperse phase that was lost on the paddle of the overhead mechanical stirrer was 
recovered and weighed. The dispersions were then weighed in order to evaluate the water 
evaporation due to high temperature and rapid stirring during production. The extent of water 
loss due to evaporation was calculated as shown in Equations 1 and 2, concerning MAD and 
NLC respectively: 
water loss = W MO/P407/H20 - (Wdp + Wdisp)      (1) 
water loss = W Tris/Tric/P188 sol 2.5% - (Wdp + Wdisp)     (2) 
where W MO/P407/H2O is the weight of monoglyceride/poloxamer and water before dispersion; 
W Tris/Tric/P188 sol 2.5% is the weight of the lipidic mixture (tristearin/tricaprin 2:1 w/w) and the 
aqueous Poloxamer 188 solution, Wdp is the weight of disperse phase lost on the paddle; and 
Wdisp is the weight of dispersion after production.  
MAD dispersions was then filtered through filter paper (Whatman ®, 90mm Dia, England) in 
order to separate big monoglyceride-poloxamer aggregates. After filtration, both dispersion and 
filter were weighed. Finally, the filter was left to desiccate in an oven at 70°C for 12 hours and 
again weighed. 
 
3.2.2 Particle density 
In order to measure the particle density of MAD and NLC, eight aliquots of dispersion (1 ml 
each) were centrifuged 4 times at 20000 g for 20 min. The precipitates were collected and 
suspended in 1 ml of water. 200 µl of this suspension were poured on a glass watch previously 
weighted and left to desiccate, afterwards the glass watch was weighted and the particles 
weight was calculated by difference. The particles density was calculated through the “density = 
mass/volume” equation. 
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3.2.3 Photon correlation spectroscopy (PCS) 
Photon correlation spectroscopy (PCS) is a technique used to determine the mean particle size 
diameter (mean PCS diameter) and the width of the particle size distribution expressed as 
polydispersity index (PI) [124-127]. The measurement using PCS is based on the light 
scattering phenomena in which the statistical intensity fluctuations of the scattered light from the 
particles in the measuring cell are measured. These fluctuations are due to the random 
movement of the particles in the dispersion medium because of the Brownian motion of the 
dispersion medium molecules (e.g. water). The measuring range of PCS is approximately from 
3 nm to approximately 3 μm.  
Usually a PCS device consists of a laser light which is focused to illuminate a small volume of 
the sample, which is a dilute suspension of particles. The light scattered from these particles is 
collected again by a lens and its intensity is measured by a photomultiplier. The diffusion rate of 
the particles depends on their size (at a known fluid viscosity and temperature). Hence, the size 
of these particles can be calculated from the rate of fluctuation of the scattered light intensity. 
The lower particle size limit for a measurement is determined by the scattering intensity and the 
experimental noise. When the suspended particles are small, they diffuse relatively fast, and the 
fluctuations in the scattered light are rapid. On the other hand, if the particles are large, they 
move slowly, and the fluctuations in the scattered light are slow. The detected intensity signals 
are used to calculate the auto-correlation function G(τ), from the decay of this correlation 
function the diffusion coefficient D of the particles is obtained. Once the diffusion coefficient is 
known, the equivalent diffusional spherical diameter can be calculated applying the Stokes-
Einstein equation, which relates the diffusion coefficient D of a spherical particle to its diameter 
r:  
ݎ ൌ ݇ܶ3ߨߩܦ 
where ρ is the viscosity of the surrounding medium, k is Boltzmann’s constant, T is the absolute 
temperature.  
The apparatus consists of a laser, a temperature controlled sample cell and a photomultiplier for 
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the detection of the scattered light at a certain angle (e.g. 90º or 173º) [125]. The photomultiplier 
(or photodiode in the new apparatus) signal is transferred to a correlator for calculation of the 
G(τ). This G(τ) is after that sent to a microprocessor for the calculation of D and the correlated 
mean particle size.  
As it was previously mentioned, small particles diffuse faster than large ones, causing a 
stronger fluctuation in the scattering signal and a more rapid decaying G(τ). For a monodisperse 
particle population G(τ) is a single exponential, but if more than one size of particles is present 
the function is polyexponential. Deviation from a single exponential is used to calculate the PI, 
which is a measure of the width of the size distribution. The PI is 0.0 when a monodisperse 
particles population is measured. PI values of around 0.10-0.20 indicate a relatively narrow 
distribution, values of 0.5 and higher are obtained in case of very broad distributions. 
Submicron particle size analysis was performed using a Zetasizer 3000 PCS (Malvern Instr., 
Malvern, England) equipped with a 5 mW helium neon laser with a wavelength output of 633 nm. 
The dispersant refractive index was 1.33 and the absorbance was 0.00. Glassware was cleaned 
of dust by washing with detergent and rinsing twice with sterile water. Measurements were 
made at 25° C at an angle of 90° with a run time of at least 180 sec. Samples were diluted with 
bidistilled water in a 1:10 v/v ratio. Data were analysed using the “CONTIN” method [128]. 
 
3.2.4 Sedimentation Field Flow Fractionation (SdFFF) 
Sedimentation Field-Flow Fractionation (SdFFF) is a name describing a group of separation 
methods constituting a subclass of general field-flow fractionation (FFF).  
SdFFF technique is ideally suited for the characterization of nanoparticles with highest 
resolution since it can separate nanoparticles by size and density in the range of 50 nm up to 
several µm. In case of very dense particles, such as gold sols, particles down to 10 nm can be 
analysed. Two identically sized particles can be still separated by Sd-FFF into two peaks, when 
the density is different.  
In SdFFF (Fig. 16) the separation force is established by a centrifugal field, which is generated 
		
3. Methods 
	
	 	
42
by spinning the complete circular SdFFF channel at a high rate. The bigger and denser particles 
are forced more in the direction of the bottom wall (outer wall) than the smaller particles. Thus 
the bigger particles are eluted later from the SdFFF channel as they are located in slower 
streamlines in the channel than the smaller particles which are located in faster stream lines. 
Typical spinning rates used in SdFFF go up to 2500 rpm. To ensure a high resolution over a 
broad size range, spinning gradients are used for the Sedimentation Field-Flow Fractionation 
separations as well. 
 
 
Figure 16. Schematic representation of Sd-FFF apparatus. 
 
A SdFFF system was employed to determine the size distribution of particles (PSD) by 
converting the fractograms, i.e. the graphical results, assuming the particle density is known 
[129]. 
The SdFFF was a Model S101 (Postnova Analytics, Salt Lake City, UT, USA) with hastelloy C 
channel walls. The rotor radius r was 15.5 cm. Nominal channel dimensions, cut from a Mylar 
spacer, were 90 cm (tip-to-tip length), 2 cm (breadth) and 0.0254 cm (thickness). The void 
volume of 4.86 cm3 was experimentally determined from injections of sodium benzoate. An 
HPLC Pump model 422 Master (Kontron Instruments, Milan, Italy) was used to deliver the 
carrier solution. The outlet tube from the channel was connected to a UV detector operating at 
240 nm (Uvidec 100, Jasco Ltd., Tokyo, Japan).  
The mobile phase was a 0.01% v/v solution of FL-70 in Milli-Q water (Millipore S.p.A., 
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Vimodrone, Milan, Italy) pumped at 2.0 ml/min and monitored in each run. Fifty microliter 
samples were injected as they were through a 50 µL Rheodyne loop valve. 
The fractions were automatically collected by a Model 2110 fraction collector positioned at the 
end of the SdFFF system (Bio Rad laboratories, UK) after setting a collecting time of 90 sec. 
The volume of each fraction was 3 ml.  
The analyses were performed by Dr.Contado of the University of Ferrara. 
 
3.2.5 Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Cryogenic Transmission Electron Microscopy (Cryo-TEM) is an electron microscopic technique 
on freezed the biological samples to view the sample with the least possible distortion and the 
fewest possible artefacts with respect to the original sample.  
In cryo-TEM, the freezing of the sample is done in ethane slush to produce vitreous, or non-
crystalline, ice. The frozen sample grid is then kept at liquid nitrogen temperature in the electron 
microscope and digital micrographs are collected with a camera. 
The advantages of cryo-TEM over traditional TEM techniques include the preservation of the 
sample in a near-native hydrated state without the distortions from stains or fixatives needed for 
traditional TEM. With image processing and averaging of multiple images, cyro-TEM provides 
high resolution information (below 10 angstroms). 
In order to analyse the morphology of the produced nanoparticles, a Zeiss EM922 Omega 
(Zeiss SMT, Oberkochen, Germany) transmission electron microscope equipped with a 
cryoholder (CT3500, Gatan, Munich, Germany) was used. 
Before the analysis, samples were vitrified [130]. In particular, a drop of the sample was put on 
an untreated pure copper transmission electron microscopy (TEM) grid (600 mesh, Science 
Services, Munich, Germany), where most of the liquid was removed with blotting paper leaving 
a thin film stretched over the grid holes. The specimens were instantly shock frozen by rapid 
immersion into liquid ethane and cooled to approximately 90K by liquid nitrogen in a 
temperature-controlled freezing unit (Zeiss Cryobox, Oberkochen, Germany). The temperature 
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was monitored and kept constant in the chamber during all the sample preparation steps. After 
freezing the specimens, the remaining ethane was removed using blotting paper. The specimen 
was then transferred in the cryo-TEM apparatus. Sample temperature was kept below 100K 
throughout the examination. Specimens were examined with doses of about 1000-2000 e/nm2 
at 200 kV. Images were recorded by a CCD digital camera (Ultrascan 1000, Gatan) and 
analyzed using a GMS 1.8 software (Gatan). 
The analyses were conducted by Dr. Markus Drechsler of the University of Bayreuth (Germany). 
 
3.2.6 X-ray diffraction measurements 
Diffraction methods, in particular X-Ray scattering, are the most reliable way of carrying out 
lyotropic phase identification. Spectroscopic techniques such as NMR and freeze-fracture 
electron microscopy, when used in conjunction with X-ray diffraction, can yield useful 
complementary data. Because of the large number of phases that can be observed as a 
function of composition and temperature [131] the attention was focused on lipid-water systems.  
A common property of lipids is the segregation of polar and paraffinic moieties into distinct 
regions. A direct consequence is the ability of lipids to take up a wide variety of structure when 
mixed with water. In the lipid diffraction, there are two regions of the diffraction pattern that are 
used to identify the phase. The diffraction pattern observed in the low-angle region (from 
several hundred Å to 10 Å) specifies the crystalline lattice, identifies the symmetry of the 
structures and gives information about the long range organization of the phase, whereas from 
the diffraction observed in the wide-angle region (centred around 4 Å) information on the 
molecular packing and the short-range organization of the lipids can be observed. It must be 
noticed that the phases considered by one parameter belong to one- (lamellar phase), two- 
(hexagonal phase) and three- dimensional (cubic phase) systems. 
Low angle X-ray scattering experiments were performed at the DESY synchrotron facility on the 
A2 beamline in Hamburg, Germany. The investigated Q-range (Q = 4 sin  / , where 2 is the 
scattering angle and  = 1.50 Å the X-ray wavelength) was 0.02-0.35 Å-1. Experiments were 
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performed in the 20-40°C range. Scattering data were recorded on a bidimensional CCD 
camera of 1024 x 1024 pixels, radially averaged and corrected for the dark, detector efficiency 
and sample transmission [132]. A few wide-angle X-ray diffraction experiments were performed 
using a laboratory 3.5 kW Philips PW 1830 X-ray generator equipped with a Guinier-type 
focusing camera operating with a bent quartz crystal monochromator ( = 1.54 Å). Diffraction 
patterns were recorded on GNR Analytical Instruments Imaging Plate system. Samples were 
held in a tight vacuum cylindrical cell provided with thin Mylar windows. Diffraction data were 
collected at 20°C. 
In each experiment, a number of Bragg peaks were detected in the low angle X-ray diffraction 
region. The peak indexing was performed considering the different symmetries commonly 
observed in lipid phases [75]. From the averaged spacing of the observed peaks, the unit cell 
dimension, a, was calculated using the Bragg law. The nature of the short-range lipid 
conformation was derived analyzing the high-angle X-ray diffraction profiles [133]. 
The experiments were performed by the group of Prof. Mariani of the Marche Polytechnic 
University. 
 
3.2.7 Differential Scanning Calorimetry (DSC) 
The International Confederation of Thermal Analysis and Calorimetry (ICTAC) defines the 
thermal analysis as “a group of techniques in which a physical property of a substance is 
measured as a function of temperature whilst the substance is subjected to a controlled 
temperature program”. In this work Differential Scanning Calorimetry (DSC) analysis was 
employed to characterize the produced particles. 
DSC is usually used to get information about both the physical and the energetic properties of a 
compound or formulation. DSC measures the heat loss or gain as a result of physical or 
chemical changes within a sample as a function of the temperature. There are 2 types of DSC 
instruments, the power compensate DSC and the heat-flux DSC [134].  
The power compensate DSC consists of 2 separate ovens while the heat-flux DSC consists of 
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one oven that heat up both the reference and the sample pans (Figure 17). Heat is transferred 
through the disc (where the sample and the reference pans are placed) and through the sample 
pan to the contained sample and reference. The differential heat flow is monitored, as well as 
the sample temperature. Software linearization of the cell calibration is used to maintain 
calorimetric sensitivity. The cell has a volume of 2 ml and can be used with various inert 
atmospheres, as well as oxidizing and reducing atmospheres. Different sample pans (hermetic, 
open or sealed) allow sample volumes of 0.04 ml to 0.1 ml, which can be up to 100 mg 
depending on sample density. 
Examples of endothermic (heat-absorbing) processes are fusion (melting), boiling, sublimation, 
vaporization, desolvation and solid-solid transitions. An important exothermic, (energy is 
liberated) process is crystallization. Qualitative measurements of these processes have many 
applications, such as materials identification, study of purity, polymorphism, solvation, 
degradation quantitative and qualitative analysis, aging, glass transition temperature and 
compatibility of substances.  
Since DSC analysis allows the study of the melting and crystallization behaviour of crystalline 
material like lipid nanoparticles, DSC was used to determine the state and the degree of 
crystallinity of SLN [135-138]. 
 
 
Figure 17. The two DSC types: the power compensate DSC (left) and the heat-flux DSC (right). 
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DSC was performed by using a Mettler TA Stare calorimeter equipped with a DSC 822® 
calorimetric cell and a Mettler STAR® V 8.10 software. The reference pan was filled with 
bidistilled H2O. 
80 μl of SLN were taken from the bulk, put into the calorimetric pan, hermetically sealed and 
submitted to calorimetric analysis as follows: (i) a heating scan from 5 to 65 °C (2 °C/min); (ii) a 
cooling scan from 65 to 5 °C (4 °C/min); for at least three times. 
The analyses were performed by the group of Prof. Maria Grazia Sarpietro of the University of 
Catania. 
 
3.2.8 Micro Differential Scanning Calorimetry (Micro-DSC) 
Micro Differential Scanning Calorimetry (micro-DSC) is a technique in which the heat flux is 
measured in function of time or temperature in a controlled atmosphere. The use of a three-
dimensional flow meter allows to precisely measure the heat flow in all directions of space. The 
required sample volume is greater than in the DSC and the speed of scanning in temperature 
must be low (between 3°C/min. and 0.001°C/min.). Micro calorimetry uses a suite of 
techniques to directly measure enthalpy and heat capacity changes that arise when chemical 
reactions occur. In aqueous solutions, heat flux into or out of the sample almost always 
happens on reaction. These reactions may involve a wide variety of situations, e.g., the 
interaction of two molecules (such as a cyclodextrin and its guest), changes in the conformation 
of complex macromolecules (such as proteins or DNA), or even in the structure of very complex 
multi-molecular colloidal drug delivery systems (such as liposomes or nanoparticles). 
The measurements of Micro-DSC were carried out with a calorimeter Micro-DSC III Setaram 
(Fig.18) with the aim to determine the critical micellization temperature (CMT). The cells used to 
deposit the sample and the reference (distilled water) were the type batch (1 mL). 
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Figure 18. Micro-DSC Setaram III and closed “batch” cells. 
 
 
Two empty cells with the caps were weighed after complete drying, and the joints were chosen 
to obtain the same mass (± 0.2 mg). The sample and the reference should be introduced to the 
cells at room temperature and weighed for the identical mass (± 0.3 mg). After their insertions 
into the oven at room temperature, the temperature of the oven was reduced until 1 °C with 
1 °C/min, and then it was kept at this constant temperature to equilibrate the thermal flow. The 
scan of temperature was performed at 0.1 °C/min until 37 °C. After this, the oven was 
maintained at this temperature for six hours, mimicking the body application of the formulation. 
Then, it was started the fusion with 0.1 °C/min to 1 °C. The analysis of the enthalpograms led to 
the determination of the CMT according to the previously described and well-known method 
[139]. The analyses were carried out in the Thermal Physics Laboratory, collaborating with Prof. 
Madeleine Djabourov during my visiting period at ESPCI-Paris Tech from November to 
December 2011. 
 
 
3.3 DRUG CONTENT 
 
3.3.1 Drug content of dispersions 
With the aim of quantifying the total drug content (free plus bonded) of dispersions after 
production, an amount of dispersion was diluted in an appropriate organic solvent, selected by a 
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solubility test previously performed on MAD, NLC and SLN. In the case of MAD, 100 µl of 
filtered dispersion were diluted with 900 µl of ethanol. In the case of NLC, 100 µl of dispersion 
were diluted with 900 µl of methanol. The mixtures were then stirred for 3 h in order to 
completely extract the drug. A sample was then filtered (0.45 μm pore diameter) and analyzed 
by high performance liquid chromatography (HPLC) for drug content. 
Drug recovery = amount of drug detected by HPLC x 100 / total amount of drug employed 
All data were the mean of 8 determinations on different batches of the same type of dispersion. 
For Sedimentation Field Flow Fractionation (SdFFF) and in vivo experiments, the amount of 
drug detected by HPLC after filtration was taken as reference of the total amount of drug. 
BC or CLO associated with particles was quantified by HPLC analyses of several fractions 
collected after the separation by SdFFF. 
 
3.3.2 Stability studies 
Physical and chemical stability studies were conducted in triplicate at 0, 1, 2 and 3 months from 
production of formulations. 
Physical stability studies were performed analysing macroscopic aspect (phase separation, 
turbidity and macroscopic viscosity) under visual inspection. 
Chemical stability was evaluated on drug loaded formulations, stored at 25°C, determining CLO 
content by HPLC analyses. Shelf life values were calculated [87]. 
Log (CLO residual content, %) was plotted against time and the slopes (m) were calculated by 
linear regression. 
The slopes (m) were then substituted into the following equation for the determination of k 
values: 
k = m x 2.303 (1) 
Shelf life values (the time for 10% loss, t90) were then calculated by the following equation: 
t90 = 0.105/k (2) 
as previously reported [140]. 
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3.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS 
HPLC technique is a suitable and accurate way to determine the content of a substance and/or 
its chemical stability.  
HPLC determinations were performed using a HPLC system (1200 Series, Agilent Technologies, 
USA) equipped with an isocratic pump, an UV-detector and a 7125 Rheodyne injection valve 
with a 50 μl loop.  
Only in the case of CLO ex-vivo studies, the instrument used was an HPLC apparatus (Waters®, 
USA) equipped with a binary pump (model 515), an autosampler (model 717 plus) and a 
tuneable absorbance detector (model 486). 
Each injection was performed in triplicate (n=3). 
Details of HPLC conditions for each drug studied are below reported in tables II to VIII. 
 
 
3.4.1 BC 
 
Table II. HPLC analysis method for BC 
Specification Details 
COLUMN C18 RP-column (Alltech® - Hypersil BDS RP18 (5 μm) 4.6 x 150 mm)  
MOBILE PHASE 0.1 M ammonium formate (pH 3) and acetonitrile 55:45 v/v 
FLOW 0.8 ml/min 
INJECTION 40 µl 
WAVE LENGHT 305 nm 
RETENTION TIME 5.8 min 
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3.4.2 Der-A 
 
Table III. HPLC analysis method for Der-A 
Specification Details 
COLUMN C18 RP-column (Grace® - Alltima RP18 (5 μm) 4.6 x 150 mm) 
MOBILE PHASE Methanol, Water 60:40 v/v 
FLOW 0.5 ml/min 
INJECTION 40 µl 
WAVE LENGHT 254 nm 
RETENTION TIME 5.4 min 
 
 
 
3.4.3 Der-B 
 
Table IV. HPLC analysis method for Der-B 
Specification Details 
COLUMN C18 RP-column (Grace® - Alltima RP18 (5 μm) 4.6 x 150 mm) 
MOBILE PHASE Methanol, Water 60:40 v/v 
FLOW 1.0 ml/min 
INJECTION 40 µl 
WAVE LENGHT 220 nm 
RETENTION TIME 11.1 min 
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3.4.4 Der-C 
 
Table V. HPLC analysis method for Der-C 
Specification Details 
COLUMN C18 RP-column (Grace® - Alltima RP18 (5 μm) 4.6 x 150 mm) 
MOBILE PHASE Methanol, Water 60:40 v/v 
FLOW 0.8 ml/min 
INJECTION 40 µl 
WAVE LENGHT 282 nm 
RETENTION TIME 5.7 min 
 
 
 
3.4.5 Der-D 
 
Table VI. HPLC analysis method for Der-D 
Specification Details 
COLUMN C18 RP RP-column (Grace® - Alltima RP18 (5 μm) 4.6 x 150 mm) 
MOBILE PHASE Methanol, Water 70:30 v/v 
FLOW 0.5 ml/min 
INJECTION 40 µl 
WAVE LENGHT 220 nm 
RETENTION TIME 6.2 min 
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3.4.6 CLO 
 
Table VII. HPLC analysis method for CLO, used with Agilent HPLC apparatus 
Specification Details 
COLUMN C18 RP-column (Agilent® - Zorbax Eclipse Plus (5 μm) 4.6 x 150 mm)  
MOBILE PHASE Methanol, Water 80:20 v/v 
FLOW 0.8 ml/min 
INJECTION 40 µl 
WAVE LENGHT 305 nm 
RETENTION TIME 6.8 min 
 
 
 
Table VIII. HPLC analysis method for CLO, used with Waters HPLC apparatus. 
Specification Details 
COLUMN C18 RP-column (Waters®, XTerra (5 µm) 3.9 x 150 mm) 
MOBILE PHASE Methanol, Water 75:25 v/v 
FLOW 0.5 ml/min 
INJECTION 50 µl 
WAVE LENGHT 233 nm 
RETENTION TIME 6.2 min 
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3.5 GEL PRODUCTION 
NLC and MAD have been respectively viscosized by the use of the polymers poloxamer 407 or 
carbomer. 
The NLC gel was produced with two different procedures. In the first case, the gel was obtained 
by diluting at 0°C a poloxamer water solution (30% w/w) to NLC in order to obtain a poloxamer 
concentration of 24% w/w in the final mixture (NLC-D). In the second case, poloxamer 407 
(24%, w/w) was directly slowly dispersed in the NLC dispersion at 0°C, under stirring until 
complete dispersion of the polymer (NLC-S). 
For the preparation of the MAD containing gel, firstly the carbomer gel was prepared. The 
polymer (2.1%, w/w) was added to bidistilled water and left to swell at room temperature to 
obtain a homogeneous and liquefied mixture. After an overnight incubation, an equal amount of 
triethanolamine was added to neutralize the solution. The obtained gel was diluted with MAD 
(1:2, v/v), resulting in a final carbomer concentration of 0.7% w/w and 3% w/w of lipids. 
 
 
3.6 PREPARATION OF SIMULATED VAGINAL FLUID 
Vaginal fluid is the resultant of fluids that comes from several strains such as uterus, cervix and 
sometimes menstrual secretions and sperm. Noteworthy, due to the limited quantity of human 
vaginal fluid and its rapid degradation once collected from its source, researchers have 
developed a simulated vaginal fluid (SVF). SVF was prepared using the procedure previously 
described by Owen et al [141]. 
Briefly, to 900 ml of distilled water contained in a beaker, NaCl (3.51 g), KOH (1.4 g), Ca(OH)2 
(0.22 g), bovine serum albumin (0.018 g), lactic acid (2.00 g), acetic acid (1.00 g), glycerol (0.16 
g), urea (0.4 g) and glucose (5.00 g) were added and stirred mechanically until complete 
dissolution. 
The pH of the mixture was then adjusted to 4.5 using HCl, and the final volume was adjusted to 
1 L. 
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3.7 RHEOLOGICAL EVALUATION OF HYDROGELS  
Rheology is the branch of physics that studies the deformation and flow of matter. The rotational 
rheometers are commonly used for measuring the rheological properties of the material.  
Rheological measurements of the gels NLC-D and NLC-S were performed on a controlled 
stress AR-G2 rheometer (TA Instrument Ltd., London, UK) using a cone-plate geometry 
(diameter 60 mm, angle 2° and gap 55 µm). A solvent trap maintained a solvent-saturated 
atmosphere around the cell and evaporation was not significant for the temperatures and time 
scales investigated (Fig.3).  
 
 
Figure 3. Ar-G2 rheometer and cone-plate geometry with solvent trap. 
 
 
Elastic (or storage) (G') and the viscous (or loss) moduli (G″) were recorded under a constant 
strain of 0.5 % to be in the linear viscoelastic regime in which the moduli are independent of the 
strain, at a frequency of 1 Hz. The presence of Pelletier diodes, placed in the lower plate, 
allowed to perform temperature sweeps from 5 to 70 °C with a precision of 0.1 °C. The elastic 
(G’) and loss (G’’) moduli were recorded, the temperature at which G’ suddenly varied 
corresponded to sol-gel transition temperature. 
Oscillatory (or dynamic) experiments were carried out. A sinusoidal shear was applied to the 
Solvent
Saturated  
vapour 
Sample
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sample, where the stress ߬ሺݐሻ	and the strain ߛሺݐሻ were defined as follows: 
߬ሺݐሻ 	ൌ 	 ߬଴ cosሺ߱ݐሻ       (1) 
ߛሺݐሻ 	ൌ 	 ߛ଴ 	cosሺ߱ݐ	 െ 	ߜሻ		      (2) 
߬଴ and ߛ଴ are, respectively, the maximal amplitudes of the stress and strain, ߱଴ ൌ 2ߨܰ, with ܰ 
the frequency and ߱ the shear pulsation and ߜ is the phase angle stress/strain. 
From the phase angle, it is possible to define various dynamic viscoelastic quantities and 
especially the elastic (or storage) modulus ܩ′ (3) and the viscous (or loss) modulus ܩ′′ (4). 
ܩᇱ ൌ 	 ఛబఊబ 	cos ߜ        (3) 
ܩᇱᇱ ൌ 	 ఛబఊబ 	sin ߜ        (4) 
The higher the G’ value, the more pronounced the elastic character and conversely, the higher 
G’’, the more pronounced the viscous properties. The elastic modulus is a measure of the 
energy stored and recovered per cycle of deformation and reflects the solid-like component of 
elastic behaviour. 
The oscillatory experiments were used mainly in order to determine the sol-gel transition 
temperature, by measuring the temperature for which G’ underwent a critical variation. 
After the common rheology measurement, SVF was added to NLC formulations in order to 
simulate the vaginal application. Considering that current topical vaginal products are generally 
applied in volumes in the range of 2-5 mL and that the volume of fluid ambient present in the 
vagina (vaginal fluid transudate and mucus) is approximately 0.5 – 0.75 ml [141], to simulate the 
dilution of formulations that might occur after application, 2 ml of each formulation was mixed to 
0.75 ml of SVF and the influence of the dilution on thermogelling and rheological properties of 
poloxamer-based hydrogels was tested. All rheological results are the means of n=3 
experiments. 
Viscosity of carbomer gels, in the absence (CLO carbomer gel) and in the presence of CLO-
MAD (CLO-MAD carbomer gel), was measured using a Brookfield dial reading viscometer 
model RTV (Brookfield engineering laboratories, Stoughton, MA, USA). Appropriate spindles 
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with different speeds (0.1 - 5 rev/min) were used to obtain the correct dial readings. Three 
readings were taken for each sample and the mean dial reading was corrected using factors 
supplied by the instrument manufacturer. 
The analyses were carried out in the Thermal Physics Laboratory, collaborating with Prof. 
Madeleine Djabourov, during my visiting period at ESPCI-Paris Tech from November to 
December 2011. 
 
 
3.8 IN VITRO TESTS 
 
3.8.1 Dialysis 
Dialysis method was used as in vitro test for BC and LD derivatives containing preparations. 
In the case of BC containing NLC and MAD and LD derivatives containing NLC, 5 ml of 
nanoparticulate dispersion were placed into a dialysis tube dipped into 100 ml of receiving 
phase, alternatively constituted of pure citrate buffer (50 mM, pH 3.5) or in mixture with ethanol 
or methanol and shaken horizontally (MS1, Minishaker, IKA, Germany) at 175 rpm and 37°C. At 
regular time intervals, 400 μl samples of receiving buffer were withdrawn and refilled again with 
fresh medium. 
In the case of Der-A SLN (2x) the test was performed using the same procedure and quantities 
but the receiving phase was constituted of water and methanol (50:50 v/v). 
 
3.8.2 Reverse dialysis method 
For the reverse dialysis method, 5 ml of MAD were directly placed into 200 ml of a stirred 
solution, constituted of citrate buffer (50 mM, pH 3.5) and methanol (50:50 v/v) in which 10 
dialysis sacs containing 1 ml of the same solution were previously immersed. The sacs were 
previously equilibrated with the solution for 30 min. At regular time intervals one dialysis bag 
was withdrawn and replaced with an equal volume of solution. The dialysis bag content was 
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assayed by HPLC for BC concentration. 
 
3.8.3 USP XXII paddle method 
The USP XXII paddle method is a procedure based on the use of an apparatus consisted of an 
approximately 25.4 mm × 34.92 mm stainless steel, 40-mesh paddle rotating at a constant 
speed of 100 rpm. The paddle was positioned inside a glass vessel placed in a water bath. 200 
ml of a poloxamer 188 solution (0.1% w/v) in phosphate buffer (0.1 M, pH 7.4) was placed in the 
vessel and stirred by the paddle. 8 ml of NLC was poured in the vessel. 
At regular time intervals, 1 ml samples were withdrawn from the vessel and refilled again with 
fresh medium. 200 l of samples were filtered through nylon filters (Steriflip, pore size 0.1 m 
pore size, Millipore, MA) and analysed by HPLC. The filters were validated with regard to drug 
adsorption.  
 
3.8.4 Franz-cells method 
For BC analyses, Franz type glass diffusion cell were assembled with a nylon membrane 
(GNWP, 0.2 µm pore size, Millipore, MA). The cell body was filled with a receptor phase 
constituted of 100 mM phosphate buffer, pH 7.4. One gram of MAD was placed into the donor 
cell compartment and tamped down on the membrane, previously moistened with the receptor 
phase. Samples of receptor phase were withdrawn after predetermined time intervals and the 
BC concentration was measured by using a HPLC analytical procedure. Each removed sample 
was replaced with an equal volume of simple receptor phase. Samples were then diluted with 
methanol in a 1:1 v/v ratio. The amount of drug released was determined by HPLC. 
For CLO analyses, the cell body was filled with a receptor phase constituted of an ethanol:water 
mixture (20:80, v/v). Experiments were carried on following a protocol previously reported [142].  
The calculated CLO concentrations were plotted as a function of time and the slopes of the lines 
were computed from the linear portion of the accumulation curve. All the obtained diffusion rates 
were determined six times in independent experiments and the mean values ± standard 
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deviations were calculated. 
 
3.8.5 Esterase degradation 
Der-A containing SLN were tested in order to create a degradation kinetic of the derivative and 
determine the amount of LD released by time. 
Alternatively, Der-A SLN dispersion or LD mother solution (50 µl) were added to a 10% v/v fetal 
calf serum (FCS) water solution in the same quantity. Thirteen Eppendorf were prepared with 
this solution and placed in a thermostatic bath at 37°C. At different time intervals, comprising 
between 0 and 1440 minutes, samples were removed from the bath and 150 µl of pure 
methanol were added to the solution. Samples were filtered with 0.22 µm nylon syringe filters 
and analysed by HPLC.  
A kinetic curve was obtained plotting the amounts of non-degraded Der-A in function of time 
(min.). 
 
3.8.6 Anticandidal activity study 
MAD and NLC samples, empty and CLO-containing, was assayed for antimicrobial activity, 
employing C. albicans ATCC 48274 as tester strain. Mother cultures of C. albicans strain have 
been set up starting from 1.5 ml of liquid nitrogen stored inoculum put in 250 ml sterile flasks 
containing 98.5 ml of liquid YEPD medium (yeast extract 0.5%, bactopeptone 1%, glucose 2%; 
Oxoid, Italy) placed at 37 °C on an orbital shaker (110 rpm). After 72 hours of culturing, C. 
albicans mother cultures reached the stationary phase of growth. For the experiment, mother 
cultures have been then properly diluted to have aliquots corresponding to 5 • 104 CFU/ml 
(Colony Forming Units). Fifty ml sterile flasks have been prepared with 800 μl of sterile 
phosphate buffer (100 mM, pH=7.4), 1000 μl of diluted C. albicans mother culture (5 • 104 
CFU/ml), and 200 μl of samples to test set up as follows, reaching a final volume of 2 ml: sterile 
water solutions of MAD and NLC samples with and without CLO (0.169 mg/ml); CLO solutions 
in DMSO (dimethyl sulfoxide, Sigma-Aldrich) at the same concentration employed for MAD and 
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NLC samples and at 1.69 mg/ml to test the strain sensitivity; negative controls with DMSO and 
sterile water have been properly processed. All the 50 ml flasks prepared as described above 
have been incubated for 2 hours at 37 °C and gently shaken (110 rpm). Then, 100 μl of each 
solution (2 ml) have been plated in Petri dishes (9 cm) previously prepared with 15 ml of YEPD 
agarized medium. The Petri plates have been then incubated at 37 °C and, after 72 hours, C. 
albicans colonies have been counted. The experiments have been processed in triplicate and 
the results expressed as CFU/plate ± standard deviation.   
Relative standard deviations and statistical significance (Student’s t test; P≤0.05) were given 
where appropriate for all bioactivity data collected. One-way ANOVA and LSD post hoc Fisher’s 
honest significant difference test were used for comparing the bioactive effects of different 
samples. 
The experiments were performed by Prof. Gianni Sacchetti group of the University of Ferrara. 
 
3.8.7 Cytotoxicity assay 
In the case of CLO forms cytotoxicity was investigated.  
Cell viability was measured by trypan blue exclusion. Trypan blue is a vital stain used to 
selectively colour dead cells blue. Live cells with intact cell membranes are not coloured. 
Since cells are very selective in the compounds that pass through the membrane, in a viable 
cell trypan blue is not absorbed, however, it traverses the membrane in a dead cell. 
Cytotoxicity test was performed on NLC dispersions and viscosized formulations, empty and 
CLO-containing. In order to better investigate the toxicity of these systems, absolute Ethanol, a 
Clotrimazole solution (1 mg/ml) in Ethanol, a Poloxamer aqueous solution (24% w/w) and a 
Poloxamer gel (24% w/w) containing Clotrimazole in a dispersed form (1 mg/ml) were tested as 
positive and negative controls.  
HeLa cells were seeded in a 24 wells plate (1 cm ²) at a concentration of 150 000 cells/ml. 1 ml 
of this suspension was filed in each well. Then, cells were incubated at 37°C for 48 hours. 
The viability of the cells was checked after 24 hours and the medium was changed in order to 
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maintain a suitable environment. After 48 hours, the medium of cells was removed by aspiration. 
Cells were washed once with PBS 1x to remove non-adherent cells and the multiwell plate was 
placed on ice in order to facilitate the correct application of thermo-reversible gel formulations. 
100µl of each sample were put in a well and 1 ml of cells medium was consequently added and 
cells were placed in an incubator at 37 °C with 5% CO2 for 24 hours.  
After the contact time, the cell medium was removed by aspiration. Cells were washed with PBS 
1x to remove all traces of FVS (Fetal Calf Serum) and 100µl of trypsin-EDTA 0.25% w/v were 
added in each well to detach the cells. Cells were then placed for 5 minutes at 37 °C 5% CO2. 
The effect of trypsin was stopped adding 400µl of cell medium. After homogenization, 50 µl of 
cells were diluted with 350 µl of Trypan blue (0.05%) in a test tube and the obtained solution 
was homogenised. 100 µl were withdrawn and put in Malassez Chamber for counting with an 
inverted microscope. Cells were differentiated between living (transparent) and dead (blue). The 
results were reported in number of viable cells and the percentage was performed in relation to 
non-treated well, which was used as a control (100% viability). 
The experiments were carried out in the Laboratory of INSERM UMR 756, collaborating with Dr. 
Vanessa Liévin-Le Moal, during my visiting period at the School of Pharmacy of the University 
Paris Sud from July to December 2011. 
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3.9 EX-VIVO TESTS 
NLC formulations (empty and CLO containing; in liquid form and viscosized) were tested in ex 
vivo permeation and penetration studies, using porcine vaginal mucosa.  
The experiments were performed in the Laboratory of UMR CNR 8612, collaborating with Prof. 
Kawthar Bouchemal, during my visiting period at the School of Pharmacy of the University of 
Paris Sud from July to December 2011. 
 
3.9.1 Preparation of phosphate buffer 
In order to simulate the systemic compartment, in which substances absorbed from mucosa are 
transported, we prepared a phosphate buffer with a pH of 7.4. 13.609 g of KH2PO4 were diluted 
in 900 ml of water contained in a beaker and stirred until complete dissolution. Then, the pH 
was adjusted to 7.4 with NaOH and the final volume of the solution adjusted to 1L. Before the 
use, the solution was filtered with Millipore Millex-GV® Syringe Driven Filter Unit (0.22 µm 
Hydrophilic PVDF). 
 
3.9.2 Animals 
Porcine vaginal mucosa was chosen because, among the larger experimental animals, the pig 
has the advantage of being remarkably similar to human in terms of anatomy, physiology, 
metabolism and histology. Furthermore, many research works have reported that excellent 
correlation was found between human and porcine vaginal tissues [143,144]. 
Experiments were carried out on female pigs (INRA Jouy en Josas, France) weighing between 
60 and 63 kg in average. The animals were fasted for 24 h, but had free access to tap water. All 
experiments on animals adhered to the Communities Commission Directive (DE/86/609/CEE) 
and were performed in conformance with the French Ministry of Agriculture Permission No. 78-
16. 
Pigs were sacrificed by intravenous injection (20 mL) of overdosed sodium phenobarbital 
(Dolethal, Vetoquinol Laboratory, Lure, France), and the vaginal mucosa was taken over a 10 
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cm length. The mucosa was placed in SVF and stored at -20°C immediately after sacrifice of 
the animal and kept at this temperature until use. It has been shown that porcine mucosa can 
be frozen during storage without affecting the mucus layer [144]. Samples were cut in 1 cm 
square pieces by means of surgical scissors to obtain intact vaginal tissue and defrosted before 
experiments at ambient temperature in the presence of SVF. 
 
3.9.3 Permeation experiment 
To evaluate CLO permeation through the skin, samples of porcine mucosa were mounted on 
standard Franz diffusion cells (area = 1.0 ± 0.1 cm2) and the receptor compartment (volume 11 
ml) was filled with phosphate buffered saline (PBS, pH 7.4). After equilibration, 1 ml of each 
NLC formulation was added to the donor compartment. The receptor compartment was stirred 
at 250 rpm in a thermostatic water bath at a temperature of 37°C. Then, at fixed time intervals, 
100 µl of the receptor phase were withdrawn and replaced with an equal amount of fresh PBS. 
The samples were filtered with Nalgene® Syringe Driven Filter Unit (0.20 µm Nylon). 
The drug amount released was assayed by means of an HPLC apparatus (Waters®, USA) 
equipped with a binary pump (model 515), an autosampler (model 717 plus) and a tuneable 
absorbance detector (model 486) set at 233 nm wavelength. A C18 column (Waters®, XTerra 
RP-18 (5 µm) 3.9 x 150 mm) was the stationary phase. The mobile phase consisted of 
MeOH/Water (75:25 v/v). The flow rate was 0.5 ml/min and the injection volume was 50 µl. 
 
3.9.4 Penetration experiment 
In the case of penetration measurements, each sample (1 ml) was applied on a portion (1 cm2) 
of the intact vaginal tissue isolated by means of surgical scissors and fixed between the donor 
and the report chamber of a Franz diffusion cell, using the same experimental protocol of the 
release measurements. The acceptor chamber was filled with PBS (pH 7.4) to maintain the 
mucosa hydrated and thermostated. 
After 8 hours from the beginning of the experiment, Clotrimazole loaded samples were removed 
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from the mucosa which was rinsed twice with MilliQ water and stored at -4°C. Tissues were 
afterwards cut in vertical slices and collected in glass vials. Drug penetrated into slices was 
extracted with 2 ml of MeOH under overnight stirring with magnetic bars. The samples obtained 
were filtered with Nalgene® Syringe Driven Filter Unit (0.20 µm Nylon) and analysed with HPLC 
using the same protocol of permeation experiments. 
 
 
3.10 IN VIVO TESTS 
 
3.10.1    Animals 
Male Sprague-Dawley rats were kept under regular lighting conditions (12 h light/dark cycle) 
and given food and water ad libitum. The experimental protocols used in the present study were 
approved by the Italian Ministry of Health (license n° 194/2008-B) and by the Ethical Committee 
of the University of Ferrara. Adequate measures were taken to minimize animal pain and 
discomfort and to limit the number of animals employed in the study. 
 
3.10.2    6-hydroxydopamine lesion  
Unilateral lesion of dopamine (DA) neurons was induced in isoflurane-anaesthetised male 
Sprague-Dawley rats (150 g; Harlan Italy; S. Pietro al Natisone, Italy) as previously described 
[145]. Eight micrograms of 6-OHDA, dissolved in 4 µl of saline containing 0.02 % ascorbic acid, 
were stereotaxically injected according to the following coordinates from bregma: antero-
posterior -4.4 mm, medio-lateral -1.2 mm, dorso-ventral -7.8 mm below dura [146]. In order to 
select the rats, which had been successfully lesioned, the rotational model was employed. Two 
weeks after 6-OHDA injection, rats were tested for denervation with a dose of amphetamine (5 
mg/kg i.p., dissolved in saline). Forty-nine rats showing a turning behavior >7 turns/min in a 
direction ipsilateral to the lesion side were enrolled in the study. Experiments were usually 
performed 6-8 weeks after lesion. Marked (>95%) reduction in striatal DA levels and tyrosine 
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hydroxylase positive DA terminals have been detected at this stage [147,148]. 
 
3.10.3    Behavioural studies in hemi-parkinsonian rats 
The 6-OHDA hemilesioned rat is a well-established model of experimental parkinsonism, in 
which hypokinetic motor disturbance primarily affects the side of the body contralateral to the 
denervated hemisphere (i.e. the toxin injection side). Parkinsonian-like disabilities were 
investigated in rats by using two previously validated behavioural tests [146,148]. The “bar test” 
measures the ability of the rat to respond to an externally imposed static posture, and provides 
information on the time to initiate a movement (akinesia) [149]. The “drag test” measures the 
ability of the forepaws to adapt to an external dynamic stimulus (i.e. dragging backwards), and 
provides information on the time to initiate and execute (bradykinesia) a movement [145, 150].  
In the bar test, the contralateral and ipsilateral forepaws of each rat were alternatively placed on 
blocks of increasing heights (3, 6 and 9 cm). The immobility time (in sec) of each paw on the 
blocks was recorded (cut-off time at each step of 20 sec) and summed. In the drag test, the 
animal was gently lifted from the tail, allowing the forepaws to rest on the table, and dragged 
backwards at a constant speed (20 cm/sec) for 100 cm. The adjusting steps made with the 
forepaws were counted by two distinct observers. Rats were trained on both motor tasks until 
their performance was reproducible. On the day of experiment, motor performance in the bar 
and drag test was evaluated before (control session) and at different time-points after drug 
administration (30, 90, 180, 300, 480 min). Drug effect has been expressed as a percent of pre-
treatment values. BC preparations (free BC, BC-MAD and BC-NLC) were given intraperitoneally 
(i.p.) at a dose of 0.3 mg/Kg (9-13 animals each group). Free BC was administered in a saline 
solution (0.9 mg/ml in NaCl 0.9% w/v). The effect of vehicle (empty MAD and empty NLC) was 
also investigated (7-9 animals each group). The dose of the lipid given to each rat was 
calculated to be 70 mg/Kg and 67 mg/Kg for NLC and MAD respectively. 
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3.10.4    Statistical analysis 
Statistical analysis was performed on percent data by one-way repeated measures (RM) 
analysis of variance (ANOVA). In case ANOVA yielded to a significant F score, post-hoc 
analysis was performed by contrast analysis to determine group differences. In case a 
significant time x treatment interaction was found, the sequentially rejective Bonferroni’s test 
was used (implemented on excel spreadsheet) to determine specific differences (i.e. at the 
single time point level) between groups. P values <0.05 were considered to be statistically 
significant. 
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4. NLC AND MAD FOR THE DELIVERY OF BROMOCRIPTINE 
 
4.1 INTRODUCTION  
The use of lipid nanosystems for the therapy of brain diseases has been recently proposed 
[151,152]. Indeed, the pharmacological treatment of brain tumors, as well as neurological and 
psychiatric disorders is often hindered by the inability of potent drugs to pass the blood brain 
barrier (BBB) [153]. BBB significantly restricts water-soluble, charged and high molecular weight 
therapeutics to the vascular space, while allowing brain penetration of small and/or lipophilic 
molecules. Multiple strategies have been employed to circumvent BBB. An emerging approach 
is the use of colloidal carriers, which allow brain penetration of non-transportable drugs by 
masking their physico-chemical characteristics [154,155]. In fact, colloidal carriers represent a 
non-invasive mean of administration, which offers clinical advantages such as the reduction of 
drug dosage and side effects, the increase of drug viability, and the improvement of patient 
quality of life [156]. 
This follow-up study was aimed at investigating the use of NLC and MAD as formulations for 
controlled delivery of BC. An in-depth characterization of morphology, size, inner structure and 
drug distribution of nanosystems was made. In addition, the ability of both BC preparations to 
attenuate motor deficits in 6-hydroxydopamine (6-OHDA) hemilesioned rats, a model of PD, 
was determined in vivo and compared to that of free BC. 
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4.2 RESULTS AND DISCUSSION 
 
4.2.1 Production and characterization of dispersions 
Production of MAD was performed by the emulsification-hot homogenization method. The loss 
of disperse phase and the weight of dispersion were 0.1%  0.02 and 87%  0.2 with respect to 
W MO/P407/H20 before production, respectively. Thus the extent of water loss (calculated by 
difference) was about 13  0.2%.  
The weight of larger particles after desiccation was 10  0.5% with respect to W MO/P407 
before production. It was found that the uptake of water by large particles was 3.3-fold their 
weight. All data were the mean of eight determinations on different batches of the same type of 
dispersions. 
NLC were produced with a tristearin/tricaprin mixture by the use of homogenization/sonication 
method, obtaining stable and homogeneous dispersions. The highest loss of disperse phase 
was on the vessel (~0.8% with respect to the total weight of the lipid plus water phases before 
dispersion, 4.0  0.3% with respect to the weight of the lipid phase before dispersion). The 
extent of water loss was 0.2  0.03%. The final weight of dispersion was 99  0.3% with respect 
to the lipid plus water phases before dispersion. All data were the mean of 8 determinations on 
different batches of the same type of dispersion. 
BC recovery after the production process in the filtered dispersion was 70  0.75% of the total 
amount used for the preparation in the case of MAD and 84  0.58% in the case of NLC 
dispersions.  
Table IX summarizes the results of PCS studies conducted to determine the dimensional 
distribution of MAD and NLC dispersions, in the absence and in the presence of BC. 
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Table IX. Mean diameters of MAD and NLC as determined by PCS 
 
PARAMETER MAD dispersion MAD-BC dispersion* NLC dispersion NLC-BC dispersion* 
ZAverage 
mean diameter (nm) 198.21.2 204.81.2 196.22.4 195.13.3 
Analysis by number 
mean diameter (nm) 
780.3 
(Peak Area 99.70.1%) 
 
 
 
84.30.4 
(Peak Area 96.20.2%) 
 
230.70.3 
(Peak Area 3.80.1%) 
125.70.2 
(Peak Area 99.50.2 %) 
 
 
 
104.3 0.2 
(Peak Area 98.60.1%) 
 
263.10.2 
(Peak Area 1.40.2 %) 
Polydispersity Index 0.180.02 0.190.01 0.180.02 0.190.03 
*produced in the presence of Bromocriptine 
PCS data are means of 5 determinations on different batches of the same type of dispersion 
 
 
Both MAD and NLC had mean intensity diameters of ~200 nm. Empty MAD had a mean 
diameter of 198.2 nm, expressed as Z Average. The analysis by volume revealed a mean 
diameter of 121.0 nm. BC incorporation slightly increased the mean diameter of nanostructures 
to 204.8 nm. In-depth analysis of the distribution by volume revealed a huge peak with a mean 
diameter of 109.1 nm (84.3 % of Peak Area) and a smaller one with a mean diameter of 286.3 
nm (15.7 %). After filtration, the mean size of the larger particles measured by laser diffraction 
was 28  2.7 nm (mean  SD of three runs), ranging between 25 and 30 nm (data not shown). 
NLC dispersions were not filtered since they did not display aggregates or large microparticles. 
Empty NLC showed a mean diameter of 196.2 nm, which was not affected by BC incorporation, 
even if the amount of larger nanoparticles increased, conferring the distribution a bimodal profile. 
Dimensional analysis by volume revealed a mean diameter of 131.4 nm for the more 
conspicuous population and a mean diameter of 392.4 nm for the other. On the other hand both 
populations displayed low polydispersity indexes (0.18 and 0.19), indicating a narrow 
dimensional distribution [157].  
Size distribution was also determined by SdFFF. The fractograms obtained under the same 
separation conditions (to allow a direct comparison) were converted into PSD plots, i.e. the 
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amount of material per unit change of diameter, according to well-proven equations, by 
transforming the retention time in the diameter of the equivalent sphere (d), and the UV signal 
into a mass frequency function (dd) [158,159].  
Figure 20 shows the PSD plots of a diluted amount of BC-MAD (panel A) and BC-NLC (panel B) 
dispersions. The conversion was performed by assuming an average density of 0.0133 g/ml for 
MAD and 0.0283 g/ml for NLC.  
 
 
  
Figure 20. PSDs elaborated from the SdFFF fractograms. A) MAD particles were assumed to have a density of 
0.9692 g/ml (d = diameter of nanoparticles; dd = dimensional distribution; the dots indicate BC content, as 
determined by HPLC). B) NLC particles: assumed density 0.9690 g/ml. 
 
 
In panel A, the main peak had a maximum at ~ 130 nm and showed a small shoulder, possibly 
masking a minor population of particles of ~ 160 nm size, as also evidenced in the original 
fractogram reported in the inset of Panel A. These size distributions partly differed from PCS 
data reported in table IX. However, the cryo-TEM image reported below (Figure 21) confirms 
the presence of particles of different size, structure and possibly density, which generates 
particle masses difficult to be efficiently separated under these experimental conditions.  
NLC particles had instead a quite regular and reproducible shape, independent of their size, 
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thus also their density might be considered constant, guaranteeing a better reliability to the 
SdFFF results presented in Panel B. The graph shows a thin peak centred at ~100 nm and 
another one, smaller and broader, with a maximum at ~275 nm. These data are in good 
agreement with the PCS analysis. The apparent discrepancy in the relative proportions between 
the two peaks is an artefact introduced by the conversion into PSD, as it can be verified by 
observing the original fractogram reported on the top of panel B, where the larger peak is 
scarcely visible from the baseline, unless to zoom in the graph.  
Cryo-TEM analyses were conducted in order to investigate the internal structures of MAD and 
NLC. Figure 21 reports cryo-TEM images of a sample of non-filtered BC-MAD. 
 
 
   
Figure 21. Cryo-transmission electron microscopy images (cryo-TEM) of BC-MAD. The insets show Fast Fourier 
transforms of some particles. 
 
Well-shaped particles with a homogeneous, ordered inner structure can be observed. Upon 
closer inspection, images reveal two different internal patterns (labelled C and H), with a 
predominance of the C over the H structural motif (panel A). It should also be underlined that 
the H structural motif appears in some larger particles (panel B) with poly-"crystalline" nature, 
B A 
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whereas smaller particles show a single internal structure. Finally, particles with ordered inner 
structure and vesicular structures attached on their surface can be observed, as previously 
found by other authors in dispersions produced using monoolein and poloxamer 407 [160]. 
Fast Fourier transform (FFT) analysis was used to characterize the internal morphology of the 
particles, since FFT easily allows to obtain an optical diffractogram similar to an electron 
diffraction pattern. In this way, periodic or repeatable distances in the mesophase structure 
could be detected, together with the symmetry of the motif. According to the different internal 
morphologies shown in Figure 21, FFT evidenced two different patterns. The first, observed in 
the particles with the H structural motif, corresponds to a two dimensional (2D) hexagonal 
symmetry with 2D lattice parameters v = w = 8.2 nm (labelled c in panel B) and γ = 120°. The 
second, observed in the particles with the C structural motif, corresponds to a rectangular 
symmetry with 2D lattice parameters v = 6.5 nm (labelled a), w = 9.8 nm (labelled b) and γ = 90°.  
The presence of particles with two different inner structures was also indicated by X-ray 
diffraction results. However, because both structures are cubic, data definitely prove that MAD 
dispersions are cubosomes.  
Figure 22 (top frames) shows the low angle X-ray diffraction profiles of empty and BC-MAD 
obtained as a function of temperature. At room temperature, diffraction profiles are 
characterized by two series of peaks, consistent with the presence of dispersed cubic phase 
particles of Pn3m and Im3m symmetry. In other words, in the presence and in the absence of 
BC, MAD dispersions can exhibit D-type or P-type structures. 
Phase coexistence in the monoolein/poloxamer 407/water disperse system has already been 
observed [89], even if in the same conditions the presence of a pure Im3m phase was also 
reported [161]. As previously discussed [162], the different structural behaviours of MAD may 
be related to differences in composition (e.g. MO quality, buffer, ionic force of the aqueous 
solution) and production procedures (e.g. ultrasonication, homogenization, temperature and 
pressure parameters). 
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Figure 22. Low-angle X-ray diffraction profiles observed from MAD and NLC samples at different temperatures. 
Measurements have been performed at 20, 25, 30 and 40°C, scattering curves are stacked consistently, following the 
direction of the gray arrows. In panels A and B, small arrows indicate the peak indexing: upward, continuous arrow, 
Im3m phase (the indicated peak sequence is [110], [200], [211]); upward, dashed arrow, Pn3m phase ([110] and 
[111]); downward, pointed arrow, H phase ([10] and [21]). 
 
 
However, the present results confirmed that at this poloxamer 407 concentration the cubic and 
not the vesicular structure is in the equilibrium state, even in the presence of BC. It should be 
noticed that both types of cubic structures detected in our preparation are bicontinuous, but the 
P-surface structure only occurs in the MO–water system when a third component is added 
[163]. Moreover, the lattice constants, which have been derived from peak positions (Table X), 
are very similar to those reported by Nakano et al. [89]. More interestingly, lattice constants are 
slightly sensitive to the presence of BC, probably due to an increased hydration of the lipid 
phases induced by BC.  
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Cryo-TEM and X-ray diffraction results are in perfect agreement. Indeed, the FFT patterns 
suggest that the H and C structural motifs correspond to planes normal to the crystallographic 
directions [111] and [110] of a cubic lattice, respectively (Figure 21). Concerning the H motif, it 
should be recalled that the projection of a 3D cubic array on 2D is hexagonal when visualized 
along the [111] direction, and that the corresponding 2D lattice parameters are related to the 
cubic unit cell dimension a by v = w = a/√2. This does neither allow to identify the space group 
of the particle internal structure, nor to differentiate between a hexagonal and a cubic structure. 
However, the comparison of 2D lattice values with the unit cell dimensions determined by X-ray 
diffraction (Table X) strongly suggests that the H particles are cubosomes with an inner cubic 
structure belonging to the Im3m space group. It is worthy of mention that only the Pn3m and 
Im3m space groups are allowed in cubosome dispersions because those are the only two 
space groups established in reversed bicontinuous cubic phases in excess water [91] or in 
reversed bicontinuous cubic phase dispersions [90]. Concerning the C-motif, the observed 2D 
lattice parameters are consistent with the ideal values for a cubic array (v = w/√2) and 
correspond to a cubic unit cell dimension of 9.8 nm. This value compares well with the unit cell 
of the Pn3m cubic phase determined in the same system by X-ray diffraction (Table X), 
indicating that C particles are cubosomes with an inner cubic structure belonging to the Pn3m 
space group. Overall, cryo-TEM images of BC-MAD dispersed particles gave strong and direct 
evidence for the coexistence of cubosomes with two different internal structures: one with a 
Pn3m space group and a lattice parameter of 9.8 nm, and another with Im3m space group and 
a lattice parameter of 11.6 nm.  
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Table X. Structure identifications and unit cell dimensions observed in the different samples at various temperatures 
Sample Temp. (°C) Phase and unit cell (nm) 
Hydrocarbon chain 
conformation 
MAD 20 1 Im3m 12.11 1.1 Pn3m 9.16   
 25 2 Im3m 12.01 Pn3m 9.11   
 30 3 Im3m 11.77 Pn3m 8.99   
 40 4 Im3m 11.25 Pn3m 8.71 5 H 6.01 
MAD/BC 20 6 Im3m 12.69 6.1 Pn3m 9.66   
 25 7 Im3m 12.64 Pn3m 9.65   
 30 8 Im3m 12.41 Pn3m 9.58   
 40 9 Im3m 11.72 Pn3m 9.14   
NLC 20-40* 10 L 4.42     β 
NLC/BC 20-40* 11 L 4.42     β 
When	samples	show	more	than	one	structure	the	one	characterized	by	the	higher	X‐ray	diffraction	profile	is	shown	in	bold.		
Error	in	unit	cells	is	±	0.02	nm									*	from	20		to	40°	C,	i.e.	20,	25,	30	and	40	°C	
 
 
X-ray diffraction experiments also reveal the thermal stability of MAD. As shown in Figure 22, 
both D- and P-type cubosomes exist at all the investigated temperatures. However, in empty 
MAD samples, two other peaks, characteristic of a 2D hexagonal space group, appeared at 
40°C. Since at this temperature the peaks of the Pn3m cubic structure broadened, it appears 
that temperature induces a D-type cubosome-to-hexasome phase transition [90,164]. 
Therefore, even if the inner structure of MAD can be highly dependent on manufacturing 
parameters and then be relevant for the properties of the dispersions, X-ray diffraction 
demonstrates that the presence of D-type cubosomes does not cause the complete loss of the 
cubic state of the particles at relatively high temperatures.  
Empty and BC-NLC dispersions have been also characterized [157].  
Figure 23 reports cryo-TEM images of NLC dispersions, prepared in the presence of BC. Both 
panels show deformed hexagonal, elongated and circular platelet-like particles, most likely 
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viewed on the top. In addition, “needle”-like structures and hemielliptical particles, characterized 
by inner striations, can be also observed.  
If the firsts are probably due to the presence of tricaprin crystals, the second ones correspond to 
edge-on view of the NLC particles. In panel B, the inset evidences one side-viewed NLC 
particle, where the distance between the layers is about 5.0 nm. 
 
 
            
Figure 23. Cryo-transmission electron microscopy images (cryo-TEM) of BC-NLC dispersions. 
 
 
Low-angle X-ray diffraction results obtained for NLC disperions as a function of temperature are 
reported in Figure 22, panels C-D. In agreement with previous observation [157], both in the 
absence and in the presence of BC, the diffraction profile is characterized by a large peak, 
whose position is unaffected by temperature and BC addition (Table X). The inner lamellar 
order and the strong structural stability of NLC, even in the presence of BC, appear also 
confirmed.  
 
 
A B 
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4.2.2 BC encapsulation 
HPLC analyses revealed that BC recovery after the production process in the filtered dispersion 
was 70  0.75 % (MAD) and 84  0.58 % (NLC) of the total amount of drug used for the 
preparation. The values of drug loss were taken in consideration to determine BC encapsulation. 
SdFFF was employed to obtain information about the drug distribution in the dispersions. During 
the fractionation, some fractions were collected and analysed by HPLC to quantify the amount 
of drug contained in the different particle populations of the disperse phase. In figure 20, the 
concentration of BC determined by HPLC is reported. BC was found to be entirely associated 
with particles in both MAD and NLC dispersions.  
The fraction corresponding to a mean diameter of about 54 nm contains 25% of the total drug, 
as shown in panel A. The highest amount of BC (46%) is contained in the most representative 
portion of nanoparticles/vesicles, having a diameter of 98 nm. The remaining 29% of BC is 
associated with the least representative population of particles, having larger diameters. In fact, 
cryo-TEM and PCS analyses showed that MAD are mainly characterized by vesicles and 
cubosomes with 90-100 nm mean diameter, and few structures with larger dimensions.  
Also for NLC, whose PSD is reported in panel B, the highest amount of BC (52%) is contained 
in the most representative fraction, characterized by particles with a mean diameter of ~103 nm. 
The fraction corresponding to a mean diameter of ~59 nm contains only 3.5% of the total drug, 
the remaining 44.5% of BC being found into a less representative population of larger particles.  
 
 
4.2.3 In vitro activity 
The method employed for the determination of drug release kinetics from nanosystems is a 
crucial point; in vitro methods have been often criticized for different reasons including: the 
difficult application to lipophilic drugs and the scarce predictivity with respect to the in vivo 
bioavailability [84,165]. 
Indeed slow drug release from nanoparticles is often claimed, but a slow appearance of drug in 
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the release medium can be an artificial result of an inadequate experimental setup rather than a 
true property of the nanosystem [157]. Accordingly, we employed different in vitro systems and 
receiving phases to analyse their effect on BC release from NLC and MAD (Table XI). 
 
 
Table XI. In vitro systems and receiving phases employed for NLC and MAD 
Method Formulations 
Receiving phase 
Agitation 
Separation 
between donor 
and receiving 
phase 
Sample 
processing 
after 
withdrawal 
Glassware 
Composition pH Volume (ml) 
Dialysis NLC/MAD 
citrate buffer 50 
mM/ethanol 
(50:50, %) 
3.5 200.0 Horizontal shaker 
Ultrafiltration 
membrane none beaker 
Dialysis NLC 
citrate buffer 50 
mM/methanol 
(80:20, %) 
3.5 200.0 Horizontal shaker 
Ultrafiltration 
membrane 
dilution with 
ethanol beaker 
Dialysis MAD 
citrate buffer 50 
mM/methanol 
(50:50, %) 
7.0 200.0 Horizontal shaker 
Ultrafiltration 
membrane 
dilution with 
methanol beaker 
Reverse 
dialysis MAD 
citrate buffer 50 
mM/methanol 
(50:50, %) 
3.5 200.0 Horizontal shaker 
Ultrafiltration 
membrane none beaker 
Reverse 
dialysis MAD 
water/ethanol 
(50:50, %) 7.0 200.0 
Horizontal 
shaker 
Ultrafiltration 
membrane none beaker 
USP 
XXII 
paddle 
NLC 
poloxamer 188 
(0.1%, w/v) in 
phosphate buffer 
(100 mM) 
7.4 200.0 Paddle none 
filtration 
(nylon, 100 nm 
pore) 
flanged 
vessel 
Franz 
cell MAD 
phosphate buffer 
(100 mM) 7.4 5.0 
Magnetic 
stirring nylon membrane none Franz cell 
 
 
 
The use of a receiving phase based on aqueous buffers (often claimed to be physiological) 
usually leads to a negligible release of BC, because of its poor solubility in media with a pH > 
pKa (5.87) [157]. In reason of this fundamental constrain, the determination of BC release was 
conducted using a receiving phase characterized by a non-physiological pH and relatively high 
proportion of organic solvents in mixture with water.  
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Figure 24. BC release kinetics from NLC determined by different dialysis method using different receiving phase. 
 
 
For instance, figure 24 reports the BC release kinetics from NLC determined by dialysis method 
using different receiving phases (see Table XI). The use of citrate pH 3.5 buffer (circles) led to 
the slowest release (3% of BC released after 10 hours), the addition of an organic solvent, 
citrate/methanol (80/20 %, v/v) caused an increase of BC release up to 12% in the same period 
of time (diamonds); the faster release of BC was observed when the amount of organic solvent 
was further increased up to 50% (citrate/ethanol, 50:50 v/v), resulting in a 60% BC release in 10 
hours. 
As comparison, in figure 24 the release profile of BC is also reported from NLC determined by 
USP XXII paddle method, using as receiving buffer a poloxamer solution in phosphate buffer 
(triangles). This in vitro method resulted in a BC release of 11% after 10 hours. 
 
		
4. NLC and MAD for the delivery of BROMOCRIPTINE 
	
	 	
80
 
Figure 25. BC release kinetics from MAD determined by different dialysis method (A) or by reverse dialysis and 
Franz cell methods (B). 
 
 
A further analysis of the effect of different release method was conducted on MAD (Fig. 25). For 
instance, figure 25A reports the effect of the receiving phase on the BC release profiles 
determined by dialysis method. Notably, in the case of MAD, plain citrate buffer (circles) or 
mixture water/methanol (50:50 v/v) (diamonds), resulted in similar profiles, characterized by BC 
release, after 12 h, comprised in the range of 30-35%. A remarkably higher BC release (58% 
after 12 h) was observed when, as receiving phase, a mixture of citrate/ethanol (50:50 v/v) was 
employed. These results reflect the influence of the organic phase on the solubility of BC. 
Furthermore, figure 25B reports the BC release kinetics from MAD obtained by reverse dialysis 
and Franz cell methods. In the case of reverse dialysis, two receiving phases were tested, 
namely citrate/ethanol (50:50 v/v) (squares), or water/methanol (80:20 v/v) (diamonds) mixtures. 
In both cases BC was released from MAD more rapidly with respect to the other above reported 
experimental conditions, in fact 60% of release was reached within 4 h. The presence of ethanol 
promotes the release of BC because the solvent interacts with the MAD components [88], 
presumably resulting in a final disorganization of the cubic structure and drug leakage. Lastly 
we tested the Franz cell method using a dialysis membrane and 0.1 M phosphate buffer (pH 
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7.4) as receiving phase, that resulted in an almost negligible BC release within a period of 24 h 
(BC < 0.8%). 
 
4.2.4 In vivo tests 
In 6-OHDA hemilesioned rats, motor impairment mainly affects the side of the body 
contralateral to the denervated hemisphere (i.e. the toxin injection side). Consistently, the 
immobility time of the ipsilateral paw (35.7 ±1.9 sec; n=42) was lower compared to that of the 
contralateral (parkinsonian) one (47.4 ± 1.9, n=42). Moreover, the number of steps made by the 
ipsilateral paw was higher (11.1 ± 0.4; n=46) than that made by the contralateral one (1.9 ± 0.1; 
n=46).   
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Figure 26. Systemic administration via i.p. of free bromocriptine (BC) and bromocriptine encapsulated in MAD (BC-
MAD) or nanoparticles (BC-NLC) in hemiparkinsonian rats attenuated akinesia in the bar test. The administered dose 
of BC was always 0.3 mg/Kg. Rats injected with vehicles (empty MAD or NLC) are also shown. Immobility time was 
calculated at different time-points (30, 90, 180, 300 and 480 min from injection) both at the contralateral (panel A) and 
ipsilateral (panel B) forepaw (in sec), and expressed as percent of pre-treatment values. Data are means ± SEM of 7-
11 animals per group. 
**p<0.01 different from empty NLC. 
°°p<0.01 different from empty MAD and NLC. 
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Repeated measure ANOVA on the immobility time at the contralateral paw in the bar test (Fig. 
26A) revealed main effects of treatment (F4,36=15.83, p<0.0001) and time (F4,155=7.51, 
p<0.0001), and a time x treatment interaction (F16,155=3.58, p<0.0001). Post-hoc analysis 
showed that both free BC and BC-NLC reduced the time spent on bar (i.e. attenuated akinesia) 
compared to vehicle-treated animals, although the action of BC-NLC was more prolonged (Fig. 
26A). Indeed, both free BC and BC-NLC produced a significant reduction of akinesia 30 min 
after administration (~77 and ~71 % of control, respectively) and were maximally effective after 
90 min (~63 and ~65 % of control, respectively). However, the effect of free BC was not 
significant after 3 hr (~93 %) whereas that of BC-NLC was still detectable up to 3 hr after 
administration (~80 %). No significant changes of the immobility time at the ipsilateral paw were 
induced by any BC formulations (Fig. 26B). 
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Figure 27. Systemic administration via i.p. of free bromocriptine (BC) and bromocriptine encapsulated in MAD (BC-
MAD) or nanoparticles (BC-NLC) in hemiparkinsonian rats attenuated akinesia/bradykinesia in the drag test. The 
administered dose of BC was always 0.3 mg/Kg. Rats injected with vehicles (empty MAD or NLC) are also shown. 
The number of steps was calculated at different time-points (30, 90, 180, 300 and 480 min from injection) both at the 
contralateral (panel A) and ipsilateral (panel B) forepaw, and expressed as percent of pre-treatment values. Data are 
means ± SEM of 7-13 animals per group. 
*p<0.05; **p<0.01 different from empty NLC. 
°°p<0.01 different from empty MAD and NLC. 
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Repeated measure ANOVA on the number of steps at the contralateral paw in the drag test (Fig. 
27A) revealed main effects of treatment (F4,36=41.31, p<0.0001) and time (F4,185=3.38, 
p=0.0106) and a significant time x treatment interaction (F16,185=3.80, p<0.0001). Post hoc 
analysis revealed that the three BC preparations improved stepping activity at the contralateral 
paw although with different efficacies and time-courses. As shown in the bar test, both free BC 
and BC-NLC elevated stepping activity at 30 min after administration (both ~190 % of control). 
However, the effect of free BC vanished after 3 hr (~125 %) whereas that of BC-NLC was 
significant both at 3 hr (~165 %) and 5 hr (~205 %) after administration. At 8 hr after 
administration, rats treated with BC-NLC still showed an elevated stepping activity (~160 %), 
although this value did not reach the level of statistical significance. At variance with the bar test, 
BC-MAD was able to attenuate motor disability in the drag test, causing a mild elevation at 3 hr 
(~131 %) and 5 hr (~132 %) from administration.   
Also stepping activity at the ipsilateral paw was affected by BC treatment (Fig. 27B). Repeated 
measure ANOVA on the number of steps at the ipsilateral paw did not reveal main effect of 
treatment (F4,36=0.96, p=0.44) but a significant effect of time (F4,185=9.82, p<0.0001) and a time 
x treatment interaction (F16,185=3.43, p<0.0001). Post hoc analysis showed that among the 
different BC formulations, only free BC improved stepping activity at the ipsilateral paw, 
specifically at 30 min after administration (~139 %). 
Among the various therapeutic applications of BC, we chose to focus on the antiparkinsonian 
activity since great therapeutic value has been attributed to formulations capable to provide 
continuous DA receptor stimulation [166,167]. Indeed, it has been demonstrated that long-term 
side effects of L-DOPA (mainly dyskinesia) arise from non-physiological “pulsatile” stimulation of 
DA receptors, which parallels plasmatic drug levels [168]. Thus, continuous delivery or 
sustained release formulations of L-DOPA have been proved to be less dyskinesiogenic than 
conventional formulations. Consistently, DA receptor agonists (the most effective alternative to 
L-DOPA) are less dyskinesiogenic than L-DOPA, probably due to the longer half-life. Achieving 
a stable and prolonged DA receptor stimulation may also be advantageous in the case of DA 
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agonists, as it allows for a reduction of the frequency of administration and occurrence of side 
effects at peak levels. In the present study we employed two different behavioural tests 
providing complementary information on motor function: the bar and the drag tests. The 
responses to BC and its NLC formulation were consistent in both tests. Thus, BC caused a 
reduction of immobility time (i.e. reduced akinesia) and improvement of stepping activity (i.e 
reduced akinesia/bradykinesia), which lasted for at least 90 min and disappeared after 3 h from 
administration. BC encapsulated in NLC essentially mimicked these effects providing a more 
prolonged attenuation of motor disability which lasted for at least 5 h and vanished within 8 hr. 
The obtained results extend our previous finding [157] and confirm the ability of BC-NLC to 
provide longer lasting therapeutic benefit compared to conventional BC formulations. The 
finding that free BC caused a rapid and transient (30 min) elevation of stepping also at the 
ipsilateral paw may reflect differences in drugs kinetics since it was not replicated by BC-NLC. 
In fact, in keeping with the view that conventional BC preparations result in higher peak levels, 
BC might also improve motility at the ipsilateral paw, which is controlled by the undenervated 
striatum.  
Quite remarkably, BC-MAD was ineffective in the bar test and caused only a mild and delayed 
elevation of stepping activity in the drag test. 
The different in vivo efficacies of BC-MAD and BC-NLC could be attributed to differences in 
nanoparticulate morphology. In fact, the former are characterized by the coexistence of 
cubosomes and vesicles while the latter are solid matrix systems.  
It has been demonstrated that the intraperitoneal administration prolongs the blood circulation of 
colloidal drug carriers with respect to the intravenous administration, due to slow absorption of 
the carrier from the abdominal cavity [169]. On the other hand it is known that colloidal drug 
carriers are rapidly opsonised and cleared by the macrophages of the reticulo-endothelial 
system (RES). Thus, as a general rule, nanosystems are mostly taken up by the liver and the 
spleen within minutes after systemic administration [170]. In the case of BC-MAD, it can be 
hypothesized that cubosomes are mainly sequestered by the peritoneal and RES macrophages, 
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as shown for liposomes and nanoparticles [171,172]. Therefore, the mild and sustained effect of 
BC-MAD may be due to the smaller vesicular liquid-like component of MAD that is responsible 
for prolonging the half-life of the incorporated drug, having a long circulating time. 
Conversely, the NLC structure allows to provide therapeutic BC concentrations to the brain for a 
long period of time [157]. This might be related to the ability of NLC to pass the BBB [151,155] 
and/or to a longer stability of NLC in the blood. In fact, previous studies [173] demonstrated that 
after intraperitoneal administration, nanoparticles show a biphasic absorption: an initial rapid 
distribution into blood, followed by a slow disposition from peritoneum, resulting in sustained 
drug release. Moreover NLC produced in the presence of poloxamer 188 in the aqueous phase, 
may behave as “stealth carriers”, thus being somewhat protected by opsonisation [156]. 
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5. NLC AND SLN FOR THE DELIVERY OF L-DOPA DERIVATIVES 
 
5.1 INTRODUCTION 
Parkinson’s disease (PD) is a neurodegenerative disorder associated primarily with loss of DA 
neurons in the nigrostriatal system [98]. Current therapy for PD is essentially symptomatic, and 
L-dopa (LD), the direct precursor of DA, is the treatment of choice for this neurodegenerative 
disease, despite the fact that several DA receptor agonists have been introduced for the 
treatment of PD [174]. LD is readily transported across the blood–brain barrier and is converted 
to DA by aromatic l-aminoacid decarboxylase (AADC). 
After a good initial response, complications are associated with long-term therapy; these include 
motor fluctuations, dyskinesias, mental changes and loss of efficacy [175]. The main 
disadvantages of LD are low water solubility, its sensitivity to chemical and enzymatic oxidation 
and peripheral decarboxylation. With the aim to prolong the pharmacological activity, enhance 
absorption and provide a protection against metabolism, the group of Professor Di Stefano at 
the University of Chieti studied LD derivatives as potential prodrugs [117, 119, 176]. All the new 
compounds showed chemical stability at acidic pH and also at the physiological pH; a relatively 
slow release of LD in rat and human plasma was observed. However, all the compounds are 
characterized by a very low solubility in water, limiting their administration. 
NLC and SLN have been used as drug carriers with the aim to enhance solubility, control the 
delivery, prolong the prodrug effect and reduce the toxicity.  
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5.2 RESULTS AND DISCUSSION 
 
5.2.1 Characterization of dispersions 
The NLC were obtained by dispersion of the lipidic phase in the aqueous phase. Four new 
synthetized LD derivatives, named Der-A, Der-B, Der-C and Der-D, were used as drug models 
as reported in chapters 2 and 3. 
After production, nanoparticles were characterized in terms of morphology and dimensions. 
Size and distribution of NLC were determined using the photon correlation spectroscopy (PCS). 
The analyses were made immediately after preparation and periodically at regular intervals for 2 
months, in order to investigate the stability of nanoparticles by time.  
In tables XII and XIII are reported the values of mean diameters and polydispersities obtained 
within two months.  
 
 
Table XII. Mean diameters of NLC as determined by PCS 
Day	
Mean	diameter	(nm)	±	s.d.	
NLC	 Der‐A	NLC	 Der‐B	NLC	 Der‐C	NLC	 Der‐D	NLC	
0	 191.5	±	3.7	 197.0	±	2.1	 180.1	±	1.0	 188.5	±	2.9	 194.1	±	2.1	
10	 193.8	±	1.6	 193.7	±	2.1	 n.d.	 n.d.	 196.6	±	1.6	
20	 n.d.	 198.7	±	3.5	 n.d.	 n.d.	 188.3	±	0.6	
30	 192.1	±	5.5	 192.3	±	0.8	 186.9	±	1.4	 189.6	±	1.3	 n.d.	
40	 n.d.	 187.9	±	3.2	 n.d.	 n.d.	 188.6	±	0.5	
50	 n.d.	 193.8	±	0.3	 n.d.	 n.d.	 186.9	±	1.3	
60	 188.2	±	0.9	 186.6	±	1.1	 186.8	±	5.2	 182.8	±	0.8	 186.8	±	3.5	
s.d.	=	standard	deviation	calculated	after	5	determinations	on	different	batches	of	the	same	type	of	dispersion	
n.d.	=	non	determined	
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Table XIII. Polidispersity indexes of NLC as determined by PCS 
Day	
Polydispersity	±	s.d.	
NLC	 Der‐A	NLC	 Der‐B	NLC	 Der‐C	NLC	 Der‐D	NLC	
0	 0.11	±	0.02	 0.20	±	0.04	 0.36	±	0.01	 0.21	±	0.01	 0.21	±	0.02	
10	 0.16	±	0.01	 0.22	±	0.02	 n.d.	 n.d.	 0.21	±	0.01	
20	 n.d.	 0.20	±	0.02	 n.d.	 n.d.	 0.21	±	0.01	
30	 0.19	±	0.07	 0.25	±	0.04	 0.25	±	0.01	 0.27	±	0.01	 n.d.	
40	 n.d.	 0.26	±	0.05	 n.d.	 n.d.	 0.25	±	0.01	
50	 n.d.	 0.24	±	0.04	 n.d.	 n.d.	 0.20	±	0.03	
60	 0.24	±	0.04	 0.21	±	0.02	 0.25	±	0.01	 0.24	±	0.01	 0.20	±	0.02	
s.d.	=	standard	deviation	calculated	after	5	determinations	on	different	batches	of	the	same	type	of	dispersion	
n.d.	=	non	determined	
 
 
Analysing the obtained values, it should be noted that in general a decrease of about 5-10 nm 
of the diameters occur by time. In addition, there are no difference in size between empty and 
drug containing NLC. Concerning the polydispersity indexes, empty NLC showed an increase of 
0.1 units by time, while other formulations no variations were remarked, indicating that also in 
the case of derivatives containing, NLC are mono-disperse maintaining its size over time. 
Cryo-transmission electron microscopy allowed an investigation of the inner structure of 
nanosized formulations, empty and derivatives containing. In figure 1, the cryo-TEM images of 
Der-A and Der-B containing NLC are reported as an example. No differences in term of 
morphology are evident for Der-C and Der-D NLC. As shown in figure 28, the structure of 
nanoparticles appears round and elliptical in shape due to the position of the nanoparticle with 
respect to the site of observation, i.e. round if the nanoparticle is placed at 180°, needle-like if 
disposed at 90°, elliptical in intermediate positions [159].  
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Figure 28. Cryo-transmission electron microscopy images (cryo-TEM) of Der-A NLC (Panel A) and Der-B NLC 
(Panel B). Data are the mean of 5 determinations on different dispersions. 
 
 
5.2.2 Prodrug recovery 
The amount of drug encapsulated in NLC was evaluated by high-performance liquid 
chromatography (HPLC) using a reversed-phase column as described in the experimental 
section. As reported in Table XIV, drug recovery after NLC production was almost quantitative 
of the total amount used for the preparation, except for Der-B. The recovery was 72.91% in the 
case of Der-A NLC, 75.31% in the case of Der-C and 81.87% in the case of Der-C NLC 
dispersions. 
Der-B NLC showed a drug incorporation of 24.57% ± 5.89, probably due to the loss of the active 
substance during the preparation procedure, especially when the lipid phase is added to the 
poloxamer aqueous solution. 
 
 
 
 
 
A B
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Table XIV. LD derivatives content in NLC  
	 %	recovery	 s.d.	
Der‐A	NLC	 72.91	 15.45	
Der‐B	NLC	 24.75	 5.89	
Der‐C	NLC	 75.31	 10.68	
Der‐D	NLC	 81.87	 18.67	
 
The	reported	results	represent	the	average	of	four	independent	experiments	±	s.d.	
 
 
5.2.3 In vitro experiments 
The in vitro release from derivatives-containing NLC was studied by the dialysis method, 
mimicking the conditions of a release after in vivo intraperitoneal administration of the NPs 
dispersions.  
The obtained results are summarized in Figure 29. It can be observed that all NLC formulations 
provide a controlled release of the drug.  
 
 
Figure 29. LD derivatives release kinetics from NLC determined by dialysis method 
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In particular, after the first hour Der-A and Der-B NLC released the 20% of total drug content, 
while Der-C and Der-D NLC released a higher amount being 25-30%. After 24 hours, the drug 
released reached almost 70% of total drug content as reported in table XV.  
 
 
Table XV. Percentages of derivatives release after 24 hours. 
	 %	release	 s.d.	
Der‐A	NLC	 68.24	 4.70	
Der‐B	NLC	 62.50	 3.04	
Der‐C	NLC	 76.90	 5.73	
Der‐D	NLC	 62.14	 2.52	
 
The	reported	results	represent	the	average	of	three	independent	experiments	±	s.d.	
 
 
From the analyses of the obtained data, it is possible to notify that Der-C NLC showed the 
greater percentages of release if compared to other derivatives containing NLC. 
However, analysing the drug recovery and in vitro results together, it is noteworthy that Der-A 
NLC are characterized by the best profile because they combine high percentages of drug 
recovery with great kinetics release in 24 hours. These results induced us to choose Der-A NLC 
dispersions for the subsequent in vivo tests. 
 
 
5.2.4 In vivo tests 
Firstly, the rats subjected to these experiments, were damaged with 6-OHDA (emiparkinsonians 
rats). The lesion with 6-OHDA was made unilaterally, presenting an important motor deficit in 
the contralateral body part at the site of injury.  
After the lesion, rats were stabled and kept to rest for a period of two weeks, after which it was 
performed a behavioural test to evaluate the preliminary level of depletion (rotarod test). The 
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test allowed assessing the overall physical activity that consists in the evaluation of coordination, 
posture, balance and resistance. Evaluation of motor performance was done by the bar and 
drag tests. 
The bar test obtained results, comparing the LD (used as positive control) with the derivatives-
containing NLC, are showed in Table XVI. 
 
 
Table XVI. Time of permanence on the lignum support. 
	
Control	 30	min.	 90	min.	
IL	 CL	 IL	 CL	 IL	 CL	
LD	(sec.)	 36.0	±	10.0	 56.5	±	5.1	 20.8	±	12.2	 41.0	±	5.1	 19.3	±	5.5	 39.5	±	5.7	
Der‐A	NLC	(sec.)	 39.2	±	12.8	 55.0	±	7.0	 32.2	±	10.4	 45.6	±	11.8	 34.4	±	13.2	 49.2	±	10.4	
 
The	reported	results	represent	the	average	of	3	independent	experiments	±	s.d.	
IL:	Ipsilateral;	CL:	Controlateral	
 
 
The obtained data showed that after 30 minutes from administration the time of permanence of 
the contralateral paw in animals treated with LD and Der-A NLC are almost superimposable 
being 41 and 45.6 sec. respectively. On the other hand, after 90 minutes the LD administration 
resulted in a greater reduction of the time spent on the step (i.e. akinesia) than Der-A NLC (39.5 
sec. vs 49.2 sec.). 
In addition, after 90 min from LD administration it can be noticed a substantial difference of the 
ipsilateral paw time of permanence (19.3 sec.) if compared to the contralateral paw (39.5). 
Conversely, in the case of Der-A NLC the ipsilateral paw permanence time on the step was not 
statistically different from the data concerning the contralateral side (Table XVI). 
The drug test results, obtained counting the number of steps made by each paw, are reported in 
table XVII. 
 
		
5. NLC and SLN for the delivery of L-DOPA DERIVATIVES 
	
	 	
93
Table XVII. Number of steps made by each paw. 
	
Control	 30	min.	 90	min.	
IL	 CL	 IL	 CL	 IL	 CL	
LD	(sec.)	 14.0	±	1.3	 1.3	±	0.3	 16.3	±	1.1	 4.0	±	2.1	 15.3	±	0.9	 2.7	±	1.7	
Der‐A	NLC	(sec.)	 11.8	±	1.8	 1.3	±	0.5	 13.2	±	4.2	 2.5	±	1.4	 12.2	±	4.4	 2.7	±	1.8	
 
The	reported	results	represent	the	average	of	3	independent	experiments	±	s.d.	
IL:	Ipsilateral;	CL:	Controlateral	
 
 
On the other hand, the drag test data showed that LD and Der-A activity are superimposable. 
This result suggests the ability of NLC to successfully cross the blood-brain barrier by improving 
the pharmacological activity of the derivatives contained. In particular, the obtained data 
corroborate the results reported in literature about NLC capability to cross the intact blood-brain 
barrier via endocytosis and deliver the drug through diffusion. 
 
 
5.2.5 Der-A SLN characterization 
Considering the best characteristics shown in the previous tests and the possibility to increase 
the drug recovery, Der-A was chosen as model prodrug for SLN incorporation. The choice of 
formulating SLN for the delivery of Der-A was motivated by the necessity to increase the 
incorporation percentages obtained by the use of NLC. SLN, based on Tristearin, Labrasol and 
soybean phosphatidylcholine, were prepared, containing 0.125, 0.25 and 0.5 mg/ml of Der-A 
and named Der-A SLN (1x), Der-A SLN (2x) and Der-A SLN (4x), respectively. 
The obtained SLN were firstly characterized in dimensions by PCS. The characterization was 
performed immediately after the production and up to two months. These analyses permitted to 
evaluate the stability of formulations. 
In tables XVIII and XIX are reported the acquired results, related to mean diameters and 
polydispersity, respectively. 
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Table XVIII. Mean diameters of Der-A SLN as determined by PCS. 
Day	
Mean	diameter	(nm)	±	s.d.	
Der‐A	SLN	(1x)	 Der‐A	SLN	(2x)	 Der‐A	SLN	(4x)	
0	 158.8	±	2.	2	 161.9	±	0.8	 149.9	±	3.2	
30	 152.85	±	0.9	 164.5	±	3.7	 147.2	±	2.8	
120	 151.7	±	3.4	 160.5	±	2.4	 146.1	±	0.8	
s.d.	=	standard	deviation	calculated	after	5	determinations	on	different	batches	of	the	same	type	of	dispersion	
n.d.	=	non	determined 
 
Table XIX. Polydispersity of SLN as determined by PCS. 
Day	
Polydispersity	±	s.d.	
Der‐A	SLN	(1x)	 Der‐A	SLN	(2x)	 Der‐A	SLN	(4x)	
0	 0.37	±	0.02	 0.36	±	0.04	 0.36	±	0.01	
30	 0.40	±	0.01	 0.39	±	0.02	 0.43	±	0.03	
120	 0.38	±	0.04	 0.40	±	0.02	 0.39	±	0.02	
s.d.	=	standard	deviation	calculated	after	5	determinations	on	different	batches	of	the	same	type	of	dispersion	
n.d.	=	non	determined	
 
 
Comparing the obtained data, it can be observed that on the day of production Der-A SLN (4x) 
showed the smaller nanoparticle dimensions while Der-A SLN (2x) were characterized by the 
bigger mean diameters, even if the difference between the two formulations was of only 12 
nanometres. 
After four months, all the preparations didn’t show a revealing change in dimensions and in 
particular, Der-A SLN (2x) resulted the most stable with a change in dimensions of only 1.5 
nanometres.  
In all cases, after 120 days the polydispersity resulted practically unchanged. 
Cryo-transmission electron microscopy analyses were conducted in order to shed light on the 
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morphology of the dispersed particles in SLN dispersions. Figure 30 reports cryo-TEM images 
of SLN dispersions empty (panel A) and loaded with the prodrug (panel B). 
 
 
     
Figure 30. Cryo-transmission electron microscopy images (cryo-TEM) of empty SLN (Panel A) and Der-A SLN (2x) 
(Panel B). Data are the mean of 5 determinations on different dispersions. 
 
 
In both cases, the SLN dispersions were characterized by weak circular and ellipsoidal 
structures representing thin platelets in top view. If the particles were viewed edge-on, they 
appeared as dark rods or “needles” since, in this position, the increased thickness of the 
structures leads to a darker appearance. The rod- or needle-like particles in the electron 
micrographs were typically of a thickness of about 10 nm and below. The presence of Der-A 
didn’t affect the structure of nanoparticles. 
 
 
 
 
A B
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5.2.6 Prodrug content of formulations 
The quantity of Der-A encapsulated in SLN was determined by HPLC. As shown in table XX, 
the highest quantity of prodrug was loaded to Der-A SLN (1x), but also in the case of Der-A SLN 
(2X) the encapsulation percentage was significant, being 71.21%. 
On the contrary, in the case of Der-A SLN (4x) the quantity of loaded prodrug was only 43.36%. 
It is possible to hypothesize that, due to the high amount of Der-A to be incorporated to the SLN 
lipid phase, a great quantity of prodrug was lost during the preparation process. This evidences 
a limit especially thinking to a scaling-up development and for this reason, Der-A SLN (5x) were 
not considered in the following analyses. 
 
 
Table XX. Der-A content in SLN  
	 %	recovery	 s.d.	
Der‐A	SLN	(1x)	 83.01	 9.38	
Der‐A	SLN	(2x)	 71.21	 7.76	
Der‐A	NLC	(4x)	 43.36	 6.63	
 
The	reported	results	represent	the	average	of	four	independent	experiments	±	s.d.	
 
 
5.2.7 DSC characterization 
Calorimetric analysis on Der-A SLN (1x) and Der-A SLN (2x) were performed firstly by a heating 
scan from 5 to 65 °C (2 °C/min) and secondly by a cooling ramp from 65 to 5 °C (4 °C/min). The 
test were repeated for at least three times. 
All SLN showed the first calorimetric curve different from the other curves.  
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Figure 31. Calorimetric curves, in heating mode, of (A) empty SLN (B) Der-A SLN (1x) and (C) Der-A SLN (2x).	
 
 
The first scan calorimetric curve of empty SLN (Fig. 31A), was characterized by a main peak at 
56.4 °C and three shoulders at lower temperatures (about 43.0, 49.0 and 53.5 °C, respectively). 
In the second and third scans, we could observe: a shoulder at about 43.0 °C (overlapping that 
of the first scan), a well-defined peak at 48.4 °C (overlapping the second shoulder of the first 
scan), and a big, broad peak at about 57 °C (overlapping the third shoulder and the main peak 
of the first scan).  
Der-A SLN (1x) showed (Fig. 31B) five calorimetric signals in the first scan: a small peak at 
about 43.0 °C, two shoulders at 46.0 and 50.0 °C, respectively, a main peak at 53.0 °C and a 
shoulder at about 57.0 °C. In the second and third scans three signals were visible: a shoulder 
at about 43.0 °C (that in the first scan was a peak), a main peak at 48.3 °C and a large shoulder 
at higher temperature.  
The first calorimetric scan of Der-A SLN (2x) (Fig. 31C) showed the same signals of the first 
scan of Der-A SLN (1x) with the only exception represented by the loss of the shoulder at higher 
temperature. The second and third scans are similar to those of SLN containing 1X of prodrug. 
This behaviour could be due to a rearrangement of the molecules of the SLN on the first heating 
that remains unaltered in the subsequent scans.  
The comparison of the first calorimetric scans of unloaded and prodrug loaded SLN gave 
important information (Fig. 32A and 32B).  
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The first scans showed interesting differences with the exception of the small peak at about 
43.0 °C which was present in all SLN. With respect to empty SLN, the main peak of Der-A SLN 
moved towards lower temperature. In Der-A SLN (1x) two shoulders were present at about 
50.5 °C and 57.0 °C, respectively. In Der-A SLN (2x) only the shoulder at about 50.5 °C was 
visible. In addition the peak intensity decreased on going from empty to Der-A SLN (2x). With 
regard to the second scan, the most evident difference concerned the broad peak at about 
58.0 °C whose intensity decreased as the amount of prodrug in the SLN increased. 
 
 
 
Figure 32. Calorimetric curves, in heating mode, of (A) first scan of empty and Der-A SLN and (B) second scan of 
empty and Der-A SLN. 
 
 
These results clearly indicate that the prodrug affects the thermotropic behaviour of SLN and 
that the effect is related to the amount of prodrug loaded. This evidence was strengthened by 
the enthalpy change values (of the second scans) reported in figure 33 as a function of prodrug 
in the SLN. The enthalpy change decreases with the increase of prodrug amount in the SLN. 
These data suggest that the Der-A arranged inside the SLN and caused a decrease of the lipid 
molecules cooperativity.	
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Figure 33. Enthalpy change, as	H/H0, of empty and Der-A SLN.		
H=H‐H0;	H=enthalpy change on Der-A SLN and	H0	is the enthalpy change of empty SLN. 
 
 
5.2.8 In vitro activity  
Der-A SLN (2x) were analysed in in vitro tests and compared to a Der-A Labrasol solution (5% 
w/v). This choice was suggested to ameliorate the Der-A solubility in water (LogP 2.29 ± 0.11) []. 
Labrasol was added to the aqueous solution in the lowest quantity that allowed the complete 
dissolution of the prodrug and permit to have a similar condition to Der-A SLN (2x). 
Therefore, the in vitro release studies was conducted with the aim to determine the capability of 
SLN to control the release of Der-A. A dialysis method, having as receiving phase a solution of 
Methanol/Water 50:50 v/v was used. 
The obtained results are shown in figure 34. 
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Figure 34. Der-A release kinetics from SLN and Labrasol aqueous solution (5% w/v) determined by dialysis method  
 
 
As it can be observed, SLN showed a progressive release of Der-A within the first 8 hours. 
Subsequently, the release percentage remained constant up to 24 hours. The kinetics is typical 
of controlled release. Comparing these data with the curve obtained by Der-A dissolved in 
Labrasol solution, it is noteworthy that in the latter case the kinetics is typical of burst release. 
It is therefore possible to conclude that the inclusion of Der-A in SLN assures a perpetuated 
release over time and, at the same time, facilitates the dissolution in aqueous media. 
 
 
5.2.9 Esterase degradation 
A prodrug is a compound (drug) administered in an inactive (or significantly less active) form 
that once administered is metabolised in vivo into an active metabolite. Der-A is a prodrug of LD 
and, for this reason, the aim of this test was the evaluation of the quantity of prodrug degraded 
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that is an index of the quantity of the LD released. 
The Der-A degradation by FCS esterases was monitored by time within 24 hours and the 
obtained results were plotted in figure 35. The attention was focused on Der-A SLN (2x) and 
Der-A Labrasol aqueous solution (5% w/v). 
 
 
 
Figure 35. Der-A release kinetics from SLN and Labrasol aqueous solution (5% w/v) determined by dialysis method  
 
 
Table XXI. Der-A half-time degradation in SLN (2x) and Labrasol solution.  
	 T	½	(min.)	 s.d.	
Der‐A	SLN	(2x)	 296	 3	
Der‐A	Labrasol	solution	 87	 2	
 
The	reported	results	represent	the	average	of	three	independent	experiments	±	s.d.	
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The values of half-time degradation were extrapolated by the graph and reported in table XXI. It 
is noteworthy that the half-lives are very different in the two samples examinated. Der-A SLN 
(2x) showed a 50% Der-A degradation correspondent to a time 3.5 fold higher than the aqueous 
solution of Labrasol, being the T ½ 86 min. for the Der-A Labrasol solution and 296 min. for the 
Der-A SLN (2x). 
In addition, after 24 hours (1440 min.) the quantities of non-degraded Der-A were 34.9% for 
Labrasol solution and 12.3% for SLN (2x). 
Therefore, it can be highlighted that SLN are not only able to delay the half-life of Der-A but also 
to promote an almost complete degradation of the prodrug in 24 hours. 
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6. NLC AND MAD FOR THE DELIVERY OF CLOTRIMAZOLE 
 
6.1 INTRODUCTION 
Oral and vaginal mucosae are characterized by a complex bacterial flora, susceptible to 
infections [177].  
Candida albicans (C. albicans) is an ubiquitous fungus normally found on the skin, in the 
stomach, colon, vagina, rectum, mouth and throat [178-180]. When this organism proliferates, it 
may produce symptomatic infections ranging from relatively trivial conditions, such as oral and 
genital thrush, to crucial, systemic superinfections in immuno-depressed and chemotherapy 
patients [181,182]. 
For this reason, in recent years, interest in Candida infections, and in C. albicans in particular, 
has become huge since fatal infections have increased in number and new Candida-based 
pathologies have been recognized [183]. 
Clotrimazole (CLO), an imidazole derivative, is a synthetic antifungal agent widely used for the 
treatment of this type of infections [184]. Unfortunately, the oral administration of this active is 
not convenient, due to his severe side effects and his short half-life (3-6 hours) that requires 
frequent dosing. For these reasons, a topical administration is suitable and recommended. 
However, since CLO exhibits a very low water solubility, it needs to be incorporated into a 
proper vehicle to have right levels of topical absorption and now it is available in the 
pharmaceutical market as a 1% topical cream. In spite of this, it has been reported that users 
usually prefer gel than cream, because of its better characteristics in easiness of use, absence 
of odour and absence of colour [185]. 
In addition, another problem about vaginal products, that influences their use by women, is the 
necessity to administer the formulation several times during the day. 
In order to overcome these problems, some authors proposed the design of solid lipid 
nanoparticles (SLN) and nanoparticle lipid carrier (NLC) as delivery system for CLO, afterwards 
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they studied SLN containing CLO incorporated in an hydrophilic cream [186-187].  
Aim of the present investigation is the design of viscous nanosystems based on NLC or 
monoolein aqueous dispersion (MAD) as devices able to exert anticandidal activity. In particular 
this study described the production, characterization and comparison of NLC and MAD suitable 
for CLO mucosal administration. 
Since the nanosystem dispersion should have a viscosity enabling permanence on the mucosa 
surface, in the present investigation different gelified systems have been specifically designed 
for NLC and MAD, respectively based on carbomer and poloxamer.  
After the production, dimensional distribution and morphology of NLC and MAD have been 
investigated by Photon Correlation Spectroscopy (PCS), SdFFF (Sedimentation Field Flow 
Fractionation) and Cryo-Transmission Electron Microscopy (Cryo-TEM). CLO recovery has 
been investigated by time up to three months from production. The rheological and calorimetric 
properties of CLO containing NLC and MAD viscous forms have been studied. 
At last the anticandidal and cytotoxicity activity of CLO containing NLC and MAD has assayed 
against C. albicans and HeLa cells, respectively. 
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6.2 RESULTS AND DISCUSSION 
 
6.2.1 Characterization of dispersions 
Cryo-transmission electron microscopy allowed an investigation of the inner structure of 
nanosized formulations, empty and CLO containing (Fig. 36). In particular, the attention was 
focused on CLO containing nanoparticles. As shown in figure 36A, NLC sample is characterized 
by the presence of ovoidal and circular platelet like particles together with needle like structures 
edge on viewed. In figure 36B can be observed that in MAD sample there is a coexistence of 
vesicles and almost spherical particles with a homogeneous ordered inner structure, typical of 
cubosomes.  
 
        
Figure 36. Cryo-transmission electron microscopy images (cryo-TEM) of CLO-NLC (Panel A) and CLO-MAD (Panel 
B). Data are the mean of 5 determinations on different dispersions. 
 
In table XXII are reported the PCS measurements conducted to determine the dimensional 
distribution of the produced NLC and MAD dispersions. It was observed that both NLC and 
MAD have mean intensity diameters around 200 nm, the drug presence slightly increased 
polydispersity indexes. 
A B
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Empty NLC showed a mean diameter of 196.2 nm, which slightly increased by CLO 
incorporation, passing to 201.6 nm. Dimensional analysis by number revealed for empty NLC a 
mean diameter of 125.7 nm and a monomodal distribution, while in the presence of CLO the 
distribution profile was bimodal, with one main peak of 120 nm and another less representative 
peak of 297 nm. 
Empty MAD had a mean diameter of 198.2 nm, expressed as Z Average. The analysis by 
number revealed a mean diameter of 78.0 nm. CLO incorporation didn’t affect the 
nanostructures’ dimensions, having a mean diameter of 195.5 nm. In-depth analysis of the 
distribution by number revealed two peaks: the main one with a mean diameter of 156.2 nm and 
a second less representative peak with a mean diameter of 250.2 nm. 
 
Table XXII. Mean diameters of NLC and MAD as determined by PCS 
 
Parameter	 NLC	dispersion	 NLC‐CLO	dispersion	 MAD	dispersion	 MAD‐CLO	dispersion	
ZAverage	
mean	diameter	(nm)	 196.22.4	 201.62	 198.21.2	 195.53	
Analysis	by	number	
mean	diameter	(nm)	
125.70.2	
(Peak	Area	
99.50.2%)	
120.06.5	
(Peak	Area	
82.22.6%)	
	
297.04.4	
(Peak	Area	
17.83.2%)	
780.3	
(Peak	Area	
99.70.1%)	
156.24.0	
(Peak	Area	
82%0.5%)	
	
250.23.0	
(Peak	Area	
18%0.8%)	
Polydispersity	Index	 0.180.02	 0.240.03	 0.180.02	 0.310.05	
 
 
Size distribution was also determined by SdFFF, an elution technique that sorts particles 
depending on their specific mass. The graphical results of the separations, the fractograms, are 
converted into PSD plots, i.e. the amount of material per unit change of diameter, by 
transforming the retention time in the diameter of the equivalent sphere (d), and the UV signal 
into a mass frequency function (dd), according to well-proven equations by assuming the 
		
6. NLC and MAD for the delivery of CLOTRIMAZOLE 
	
	 	
107
density is known [129,159]. To allow a direct comparison, the fractograms were obtained under 
the same separation conditions.  
Figure 37 shows the derived PSD plots of a diluted amount of CLO-NLC (panel A) and CLO-
MAD (panel B) dispersions. The conversion was performed assuming an average density of 
0.0283 g/ml for NLC and 0.0133 g/ml for MAD.  
In figure 37A, the CLO-NLC plot shows a broad peak due to the overlapping of two particle 
populations, the first peaking at ~ 140 nm and the second at ~ 200 nm. The broad and 
composite signal evidences the presence of a heterogeneous population of particles with 
different mean diameters.  
In panel B one can observe a main peak with maximum at ~ 160 nm and a small secondary 
peak, corresponding to a minor population of particles of ~ 247 nm size. These size distribution 
is in agreement with PCS data reported in table XXII.  
 
         
Figure 37. PSDs elaborated from the SdFFF fractograms. A) NLC particles were assumed to have a density of 
0.0283 g/ml B) MAD particles; assumed density of MAD particles 0.0133 g/ml (dd = dimensional distribution; the dots 
indicate CLO content, as determined by HPLC) 
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6.2.2 Drug recovery and distribution 
As reported in Table XXIII, CLO recovery after the nanosystems production was almost 
quantitative, being 97.21% of the total amount used for the preparation in the case of NLC and 
90.62% in the case of MAD dispersions. 
 
 
Table XXIII. CLO content in NLC and MAD as a function of time  
CLO	recovery	(%)a	
Time	(days)	 in	NLC	 in	MAD	
0	 97.21±0.2	 90.62±0.4	
15	 96.05±0.1	 89.71±0.2	
30	 95.02±0.3	 85.14±0.6	
60	 94.40±0.2	 74.02±0.8	
90	 93.21±0.5	 59.03±0.2	
Shelf	life	values	
K	 0.00018	 0.00484	
t90	(days)b	 241.93	 21.87	
 
a:	as	a	function	of	initial	CLO	content.	
b:	Time	at	which	the	drug	concentration	has	lost	10%.	
The	reported	results	represent	the	average	of	four	independent	experiments	±	s.d.	
 
 
SdFFF was employed to obtain information about the drug distribution within the produced 
dispersions. During the fractionation, some fractions were collected and analysed by HPLC to 
quantify the amount of drug contained in the different particle populations of the disperse phase. 
In Figure 37, the CLO concentration determined by HPLC is graphed as the secondary y-axis in 
the PSD plots. CLO was found to be entirely associated with particles in both NLC and MAD 
dispersions, even if in both plots, the first CLO concentration value is out of the dd profile. This 
is a consequence of the fractogram-PSD conversion procedure, which excludes the data not 
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resolved from the void peak, where the lightest (smallest) particles are eluted [158]. 
In the case of NLC, whose PSD is reported in panel A, 19.45% of CLO is contained in a fraction 
characterized by particles with a mean diameter of ~60 nm, the fraction corresponding to a 
mean diameter of ~95 nm contains 17.7% of the total drug, 26.5 % of CLO is contained in 
fractions ranging between 115 and 140 nm and the remaining 36.35% of CLO is associated to a 
less representative population of larger particles.  
In the case of MAD, CLO distribution is narrower than in MAD. In fact, the fraction 
corresponding to a mean diameter of about 84 nm contains 31.1% of the total drug, as shown in 
panel A. The highest amount of CLO (35.2%) is contained in the most representative portion of 
nanoparticles/vesicles, having a mean diameter of 140 nm. The fraction corresponding to a 
mean diameter of 179 nm contains only 6.3% of the total drug, the remaining 27.4% of CLO is 
associated with the less representative population of particles, having diameters comprised 
between 200 and 300 nm.  
 
6.2.3 Stability studies 
Table XXIII reports CLO content in the different formulations as a function of time, expressed as 
percentage of the total amount used for the preparation. 
Shelf life stability was calculated plotting Log (CLO residual content, % with respect to drug 
content at time 0) against time, obtaining first order kinetics. From the slopes (m), obtained by 
linear regression, shelf life values (t90), i.e. the time at which the drug concentration has lost 
10%, were calculated and reported in Table XXIII. 
t90 calculated for CLO-NLC was longer than 8 months (241.93 days), whilst in the case of CLO-
MAD it resulted only in 21 days. These data could be due to the differences in the nanostructure 
of NLC and MAD, the former characterized by solid matrixes, the latter by a mixture of vesicles 
and cubosomes. For this reason it is hypothesized that NLC could better control the stability of 
the incorporated drug. 
The macroscopic aspect of NLC dispersions didn’t change by time; in fact, dispersions 
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maintained their white colour and the absence of aggregates also after six months from 
production. On the other hand, in the case of MAD, some aggregates were found after 2 weeks 
from production, with a slow progressive increase by time. 
 
6.2.4 Production of viscous forms 
In order to adequately adjust the viscosity of NLC and MAD, different gels based on poloxamer 
407 and carbomer were designed and produced.  
In the case of NLC, thermo-reversible gels were developed. NLC dispersions were adequately 
viscosized to obtain a thermo-reversible bioadhesive organogel, characterized by a low 
viscosity at room temperature, in order to enable an easy application onto mucosa. After 
application, the contact with the body allows the gel to increase its viscosity, controlling CLO 
diffusion. 
In the first case, NLC were viscosized by mean of poloxamer following a dilution procedure. 
Precisely, an adequate volume of NLC suspension (alternatively empty and CLO containing) 
was added at 0°C to a 30% w/w poloxamer 407 gel until a final polymer concentration of 24% 
w/w. The final solution (NLC-D) was stored at 4°C overnight and resulted homogeneous without 
aggregates. 
In the second case, NLC suspensions were viscosized following a one step process based on 
the dispersion at low temperature of solid poloxamer 407 within the aqueous phase of NLC 
(NLC-S). Also in this case, a final concentration of polymer of 24% w/w was obtainedIt has to be 
underlined that it was not possible to viscosize MAD in the same way, due to precipitation of 
MAD at low temperature. 
Thus, MAD viscosization was obtained by addition of a carbomer gel (1.2% w/w) previously 
prepared, resulting in the formation of a homogeneous whitish formulation, with an adequate 
viscosity for the mucosal administration. Differently from NLC containing gels, MAD containing 
gel was not thermo-reversible. 
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6.2.5 Rheological characterization of hydrogels 
Rheological analyses were performed both on NLC-D and NLC-S, empty and CLO-containing. 
Rheological characterizations were preformed both on the gels as such and after the addition of 
SVF in physiological quantities to each formulation. Particularly, variations in sol-gel transition 
temperatures were analysed. 
Usually, the gelling temperatures of vaginal hydrogels are considered to be suitable for vaginal 
administration when they are lower than human vaginal temperature (37.2 °C). If gelling 
temperature is higher than 37.2 °C, hydrogels will lose their gelling properties resulting in a 
leakage of the formulations from the vagina. 
Initially, the thermosensitive properties of hydrogels were evaluated considering their sol/gel 
transition temperature. The curves of G’ and G’’ obtained from preparations are presented in 
figures 38 and 39. Particularly, formulations before and after dilution with SVF respectively were 
considered. The obtained curves are typical for poloxamer systems since the elastic modulus, 
(G’) very low at solution stage, increased drastically when gelling temperature was reached. In 
fact, since a high elastic modulus is an inherent characteristic of solid materials, a phase 
change process from liquid to semisolid can be described by an increment of elastic modulus 
[188]. 
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 Tgel (°C) G’ (103 Pa) G’’ (103 Pa) δ (°) 
A) NLC-D gel 17.6 ± 0.8 2.1535 ± 0.2 1.8132 ± 0.1 0.5630 
B) CLO-NLC-D gel 17.5 ± 0.6 2.1558 ± 0.1 1.8409 ± 0.2 0.5683 
C) NLC-S gel 16.8 ± 1.2 1.6027 ± 0.1 1.5120 ± 0.1 0.2238 
D) CLO-NLC-S gel 17.4 ± 1.0 2.0899 ± 0.3 1.8537 ± 0.2 0.3141 
Tgel = sol-gel transition temperature   G’ = elastic (storage) modulus   G’’ = viscous (loss) modulus   δ = phase angle at 37.2°C 
Figure 38. Rheological characterization of NLC-D and NLC-S gels, empty and CLO-containing. 
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 Tgel (°C) G’ (103 Pa) G’’ (103 Pa) δ (°) 
E) NLC-D gel + SVF 23.7 ± 1.0 0.5704 ± 0.1 0.5752 ± 0.1 1.091 
F) CLO-NLC-D gel + SVF 24.9 ± 0.8 0.7187 ± 0.3 0.7146 ± 0.1 1.352 
G) NLC-S gel + SVF 29.3 ± 0.4 1.0447 ± 0.2 1.0862 ± 0.3 2.220 
H) CLO-NLC-S gel + SVF 29.6 ± 0.2 1.2749 ± 0.1 1.2420 ± 0.2 3.873 
Tgel = sol-gel transition temperature   G’ = elastic (storage) modulus   G’’ = viscous (loss) modulus   δ = phase angle at 37.2°C 
Figure 39. Rheological characterization of NLC-D and NLC-S gels, empty and CLO-containing, after the addition of 
SVF. 
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As can be seen from the results reported in the table linked to figure 38, gelling temperatures 
were in all cases lower than body temperature and didn’t show significant variation neither 
considering the two different methods of gelification, nor evaluating the absence or the 
presence of CLO. 
As shown in figure 39, even after addition of SVF all poloxamer systems maintained a typical 
thermoreversible behaviour, with a rapid increase of G’ values at sol-gel temperature. It is 
important to highlight that the addition of 0.75 mL of SVF resulted in a decrease of poloxamer 
concentration from 24% to 17.45% and consequently, in a dramatic increase of gelling 
temperature, remarkable in the table linked to figure 39.  
For NLC-S, the final gelling temperatures were around 30 °C, while in the case of NLC-D the 
values were about 24-25 °C. More than 10 °C of difference were observed before and after the 
addition of 2 mL of viscosized gels with 0.75 mL of SVF, about 5°C of difference were found in 
diluted samples. CLO presence didn’t cause further variations of temperature.  
The addition of SVF leads to a decrease in the elasticity of the hydrogels. As we can see from 
the table linked to figure 39, when hydrogels were diluted with SVF elastic modulus (G’) was 
always decreased. It is noteworthy that the variation of gelling temperature is not only due to the 
decrease in copolymer concentration after the dilution of the formulations, but also caused by a 
modification of the physicochemical properties of the hydrogels. In fact, the obtained results can 
be also explained by the presence of co-solutes, e.g., ions, proteins, electrolytes in the SVF 
medium, which could interact with poloxamer [189]. As demonstrated by Scherlund [190], in the 
case of poloxamers, gelation and micellization processes are strongly connected.  
Considering the loss modulus (G’’), NLC-S maintained higher values of viscosity after dilution 
with SVF than diluted hydrogels. For this reason, it is expected that these superior viscosity 
modulus will result in an increase in the spreading of the viscosized hydrogel over the vaginal 
mucosa after its in vivo administration. 
The properties of CLO-MAD carbomer gel were tested and compared to a correspondent 
carbomer gel in terms of polymer concentration. 
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After a macroscopic analysis, carbomer hydrogels appeared to be stable formulations that could 
incorporate MAD without changing their original texture properties. One possible explanation 
can be that MAD accommodate themselves in the empty spaces inside the gel’s three-
dimensional structure. 
Concerning the rheological evaluation, as shown in figure 40, both empty and CLO-MAD 
carbomer gel evidenced a non-Newtonian behaviour with pseudoplastic characteristics. The 
relationship between shear stress and shear rate was not constant and the viscosity changed 
as the shear rate was varied. In particular, in both samples a decreasing viscosity with an 
increasing shear rate was displayed. 
In addition, it can be observed that CLO-MAD carbomer gel shows a higher value of viscosity at 
low shear stress if compared to the empty formulation. This increase in viscosity could be 
attributed to the complete incorporation of MAD in carbomer gel.  
In vaginal environment, where the temperature is higher than room temperature and vaginal 
fluids cause a dilution of formulations, the cross-linked bounds inside the gel can get weak and 
can partially become degraded. For these reasons, an increase in viscosity values, when the 
shear stress is low, is a suitable characteristic for CLO-MAD Carbomer gel, because it 
preserves the formulation from an immediate degradation and permits a deposition on the site 
of action for a prolonged period of time. 
After the physiological dissolution of gel, when strong bounds become weaker, MAD and 
vesicles can come out and explain their activity directly on the vaginal mucosa, releasing CLO 
in a controlled manner. 
Taken together these considerations, a double action could be ascribed to CLO-MAD Carbomer 
gel: initially, high viscosity guarantees a localization of gel in the site of action and secondly, a 
controlled release of CLO from MAD permits a prolonged activity in the vaginal site. 
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Figure 40. Viscosity of Carbomer gel (red line) and CLO-MAD Carbomer gel (blue line) as a function of the shear 
rate 
 
 
6.2.6 Micro-DSC 
NLC-D, CLO-NLC-D, NLC-S and CLO-NLC-S were subjected to micro-DSC as described in the 
material and method section. As control, a plain solution of Poloxamer 407 (24% w/w) dispersed 
in water was examined under the same conditions (Fig. 41).  
From the analyses of heating and cooling ramp reported in figure 41, it could be observed that 
the two curves, namely endothermic peak (red) and exothermic peak (blue) are perfectly 
symmetric exhibiting the thermal equilibrium of micelle formation in this condition. In fact, the 
obtained two peaks correspond to the progressive formation and fusion of the micelles in the 
solution with increasing and decreasing temperatures. 
In calorimetric assays, it is possible to extrapolate from the micro-DSC traces the temperatures 
Tonset, Tpeak and Tendset of micelle’s formation and fusion from the Micro-DSC traces. Particularly, 
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they are the temperatures of the incipient polymer association (Tonset), the temperature of the 
maximum of the heat flow (Tpeak) and the temperature of the end of micellization process (Tendset). 
In this study, the critical micellization temperature (CMT) was defined as the Tonset that is the 
temperature resulting from the intersection of the tangent of the first inflection point of the peak 
with the baseline [191]. 
The obtained results of the thermal analysis conducted on NLC-D and NLC-S, empty and CLO-
containing, are shown in figures from 42 to 45. 
The evident variation in shape of cooling curve with respect to heating one can be attributed to 
a partial disorganization of lipids during the stationary phase when the gels NLC-D or NLC-S 
are maintained at 37° C for 6 hours. Nanoparticles, having trycaprin as component, whose 
melting point is 33° C, are subjected to a structural modification that allows a gradual release of 
CLO and its specific action in the application site. During the cooling phase, the gel, consisting 
in an organized structure of polymeric micelles and NLC, is characterized by a disorganized 
mixture of free lipids and polymer, due to the partial melting of trycaprin. As result, in the case of 
NLC-D or NLC-S (Fig. 42 and 44), when micelles form themselves again, the hydrophobic tails 
of the polymer can interact not only with each other, but also with the lipids freely present in 
solution or in aggregated to form NLC. This phenomenon is evidenced by an increase of the 
time required to form micelles of mixed nature and consequently, in a reduction of CMT. 
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Fig. 41: Heat flows versus temperature for a water solution of poloxamer F127 gel (24% w/w) during heating and 
cooling ramps. 
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Fig. 42: Heat flows versus temperature for a solution of NLC-D gel during heating and cooling ramps. 
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Fig. 43: Heat flows versus temperature for a solution of CLO-NLC-D gel during heating and cooling ramps. 
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Fig. 44: Heat flows versus temperature for a solution of NLC-S gel during heating and cooling ramps. 
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Fig. 45: Heat flows versus temperature for a solution of CLO-NLC-S gel during heating and cooling ramps. 
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The greater the disorganization of the system, the more evident the effect one can hypothesize 
that the gel network of NLC-D formed incorporates NLC without structural interactions, 
otherwise, in the case of NLC-S gel, interactions occur between the polymer in solid form and 
the NLC during the gelification, due to the dissolution of poloxamer directly in the aqueous 
phase of the formulation. This behaviour could permit an initial interaction between hydrophobic 
tails of polymer and the NLC. In this latter case, after the stationary phase at 37° C, the system 
is more destabilized and this involves greater difficulties in the formation of micelles. The 
greater disorganization of the NLC-S gels could be also highlighted with the background noise 
that appeared in fusion enthalphograms (Fig. 44 and 45). 
CMT values were extrapolated and reported in Table XXIV. While in the plain solution of 
Poloxamer gel the CMTs related to the phase of formation and fusion of micelles are slightly 
superimposable, when NLC are present there is a considerable difference between the CMT 
data obtained in the phase of formation and fusion. NLC-D gels were characterized by a 
reduction of 40% of CMT during the fusion phase, while NLC-S showed a reduction of 65%. 
 
 
Table III. CMTs obtained by enthalphograms related to formation and fusion of micelles, obtained by micro-DCS 
Sample CMT Formation (°C) CMT Fusion (°C) 
Poloxamer gel 24% w/w 9.4 ± 0.2 9.2 ± 0.1 
NLC-D gel 9.6 ± 0.1 5.8 ± 0.2 
CLO-NLC-D gel 8.9 ± 0.1 5.9 ± 0.1 
NLC-S gel 8.1 ± 0.2 2.8 ± 0.2 
CLO-NLC-S gel 7.4 ± 0.1 2.6 ± 0.1 
 
 
This trend confirms the hypothesis indicated above and suggests that despite NLC-S lose their 
thermo-reversibility after the phase at 37° C, there is an advantage in their administration. In 
fact, at body temperature, NLC-S gels disorganized themselves more efficiently ensuring a 
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improved therapeutic efficacy due to the combined action of gel and nanoparticles. 
The presence of CLO didn’t change the performance of the system. It is possible to evidence 
the presence of the active linked to the lipidic phase in background noise that can be detected 
especially in the fusion phase. 
Furthermore, in all samples a second weak peak appears at the end of micellization 
corresponding to the temperature where the micelles arrange in a crystalline structure. The 
crystallization small peak in micro-DSC could be superimposed to the sol-gel transition 
temperature in rheology. For this reason, it has been evaluated whether there was a 
correspondence between the micro-DSC and rheology data. 
Table XXV shows the crystallization temperature compared to the sol-gel temperature obtained 
by rheology analyses.  
 
 
Table XXV. Temperatures of crystallization peaks and sol-gel transition, obtained by micro-DCS and rheology 
analyses 
Sample Crystallization peak (°C) Sol-gel transition temperature (°C) 
NLC-D gel 17.89 ± 0.2 17.6 ± 0.8 
CLO-NLC-D gel 17.78 ± 0.4 17.5 ± 0.6 
NLC-S gel 17.78 ± 0.3 16.8 ± 1.2 
CLO-NLC-S gel 17.56 ± 0.6 17.4 ± 1.0 
 
 
We could observe that values are nearly superimposable both in the comparison between 
micro-DSC and rheology data, both evaluating the different gelification method used. Also in 
this case, the presence or the absence of CLO didn’t cause variation of crystallization 
temperature. These values confirmed that all formulated gels are able to change their structure, 
with a rapid passage from liquid to solid (crystalline) form, at a temperature lower than vaginal 
temperature, allowing a selective action in the site of application. 
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Considering the better performances obtained by empty and CLO containing NLC-S gels in 
calorimetric assays, these formulations were chosen for in vitro and ex vivo experiments as 
representative samples for viscous forms of NLC. 
 
6.2.7 Diffusion experiments 
To compare diffusion of CLO from the different formulations, Franz-cell diffusion method was 
used. CLO diffusion kinetics from liquid and viscosized NLC and MAD and from the commercial 
cream Canesten have been analysed. In particular, the following forms have been tested: 
CLO-NLC, CLO-MAD, CLO-NLC-S gel, CLO-MAD carbomer gel, CLO-poloxamer gel, CLO-
carbomer gel and Canesten.  
Experiments were performed at 37°C, in order to mimic the mucosal temperature. Table XXVI 
reports diffusion rates (obtained from the slope of the diffusion line), correlation coefficients and 
amount of released drug after 7 hours. 
From the obtained results, it can be observed that CLO diffusion rates from NLC and MAD are 
comparable, while the corresponding viscous forms display slower diffusion rates, as expected. 
CLO diffusion rate from Canesten is similar to those displayed by the drug in NLC and MAD. 
The slowest rate was obtained by CLO-MAD carbomer gel (0.69), while plain CLO-poloxamer 
gel exhibited the fastest one (3.1). It is interesting to note that CLO diffuses more slowly from 
NLC than from poloxamer gel, due to the semi-solid structure of nanoparticles, whilst CLO 
diffusion from MAD, being characterized by the presence of soft amphiphilic structures such as 
vesicles and cubosomes, is faster than from the corresponding plain carbomer gel. 
At last it can be observed that on one hand the presence of MAD in carbomer gel causes a 1.2-
fold reduction in CLO diffusion, on the other NLC-S gel decreases CLO diffusion with respect to 
the plain poloxamer gel (1.7-fold lower). In this respect it can be concluded that the diffusion of 
the drug is controlled both by the NLC matrix and by the network of the poloxamer gel, in 
agreement with the indications obtained by the rheological study. 
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Table XXVI. CLO diffusion data from the indicated formulations obtained by Franz cell.  
Formulation 
Diffusion rate 
(slope of the lines) 
Correlation coefficient 
Released drug 
during 7 h (µg/cm2) 
CLO-NLC 2.319 0.997 49.375 
CLO-NLC-S gel 1.812 0.998 38.560 
CLO-MAD 2.141 0.999 44.865 
CLO-MAD 
carbomer gel  
0.695 0.999 14.183 
CLO -poloxamer gel 3.101 0.999 63.320 
CLO-carbomer gel 0.839 0.998 16.655 
Canesten® 2.469 0.999 50.325 
	
CLO‐NLC:	CLO	containing	NLC;	CLO‐NLC	poloxamer	gel:	CLO‐NLC	directly	viscosized	by	poloxamer	gel,	CLO‐MAD:	CLO	
containing	MAD;	CLO‐MAD	carbomer	gel:	CLO‐MAD	diluted	with	carbomer	gel;	CLO‐poloxamer	gel:	CLO	containing	gel	
based	 on	 poloxamer	 407	 (24%	 w/w);	 CLO‐carbomer	 gel:	 CLO	 containing	 gel	 based	 on	 carbomer	 (0.7%,	 w/w);	
Canesten:	CLO‐commercial	formulation.			
 
 
6.2.8 Ex vivo study 
Ex vivo experiments were performed only on NLC formulations, considering their better stability 
by time in terms of drug loading and structure, evaluated by previous tests. 
The aim of this further characterization was the investigation of possible systemic side effects of 
CLO. Even if this drug is also administrated by oral forms, it is noteworthy the liver toxicity of 
CLO, its use as anticancer drug and the possibility of resistance especially in patients with a 
compromised immune system [192,193].  
After HPLC analyses of fractions related to permeation experiment, no CLO was found in all 
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samples withdrawn from 0 to 8 hours in the receptor compartment. Neither CLO-NLC dispersion 
nor CLO-NLC-S gel determined a passage of the active through the vaginal mucosa.  
Table XXVII shows the obtained results after penetration measurements.  
 
 
Table XVII. CLO diffusion data from the indicated formulations obtained by Franz cell. 
Sample Clotrimazole penetrated (%) 
CLO-NLC 0.33 
CLO-NLC-S gel 0.03 
 
 
The percentages of CLO penetrated related to the total amount of active calculated after drug 
recovery characterization are very low and are in accord with permeation data. 
It could be observed that CLO-NLC dispersion and CLO-NLC viscosized gel didn’t reach the 
systemic circulation and for this reason, a systemic toxicity could be avoided. 
 
6.2.9 Anticandidal activity 
NLC and MAD (0.169 mg/ml) dispersions, empty and CLO containing, have been assayed 
against C. albicans (Fig. 46). DMSO has been employed as negative control. Empty MAD and 
NLC, tested as aqueous dispersions, evidenced a significant CFU reduction capacity of 17.8% 
and 24.7% with reference to negative control respectively, due to intrinsic cytotoxicity of nano-
supports [194,195]. The difference in bioactivity between MAD and NLC was instead not 
significant (8.4%), evidencing their comparable efficacy against the yeast strain. 
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Fig 46. Clotrimazole bioactivity against C. albicans ATCC 48274 strain expressed as colony forming units (CFU) per 
plate ± standard deviation after 5 days of cell incubation with the drug free or encapsulated in different 
nanoparticulate systems 
H2O: Negative Control as sterile water; MAD: empty monoolein aqueous dispersion; NLC: empty nanostructured lipid 
carrier dispersion; CLO-MAD: Clotrimazole (0.169 mg/ml) containing MAD; CLO-NLC: Clotrimazole (0.169 mg/ml) 
containing NLC; CLO: Clotrimazole (0.169 mg/ml) in dimethyl sulfoxide (DMSO); CLO10X: Clotrimazole solution in 
DMSO (1.69 mg/ml); DMSO: Negative Control as DMSO. 
 
 
As expected, CLO-NLC and CLO-MAD showed an important decrease of C. albicans CFU, with 
an efficacy of 54.6% and 65.3% respectively if compared to the CLO-DMSO system. In fact, 
pure CLO (0.169 mg/ml) in DMSO evidenced only a 6.8% CFU reduction capacity with respect 
to the negative control (DMSO), while significant bioactivity has been instead expressed only at 
a concentration ten fold higher (1.69 mg/ml).  
Since the DMSO negative control evidenced a number of CFU comparable to that displayed by 
the negative control with sterile H2O (gap 1.9%), the differences between the CLO-nanosystems 
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and the pure CLO could be ascribed both to intrinsic cytotoxicity of the nano-matrixes and to the 
presence of incorporated CLO. It could be tentatively suppose that nanoparticles are able to 
enhance CLO penetration through fungal cell walls to inhibit ergosterol synthesis [196]. 
 
6.2.10 Cytotoxicity assay 
In figure 47 the results of the toxicity study after 24 hours of exposure of the HeLa cells are 
illustrated for empty samples in comparison to CLO-containing (1 mg/ml) ones. 
The empty solution of ethanol caused less toxicity than the relative CLO-containing solution. In 
this case CLO is completely dissolved in the organic solvent so we might think of a combined 
toxic action of solvent and solute in the same time. 
Empty NLC induced a cell vitality of 90.2%, otherwise CLO-NLC caused extended cell mortality 
and only the 27% of cells were living at the end of the experiment.  
On the contrary, CLO containing NLC-S showed a toxicity profile only slightly higher than empty 
NLC-S, resulting in a cell vitality of 74.9% for CLO NLC-S and 77.2% for NLC-S.  
A similar result was obtained in the case of a poloxamer aqueous solution (24% w/w) used as 
control. Empty poloxamer gel caused a cell vitality of 82.5% while CLO containing poloxamer 
gel 74.3%. 
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Fig 47. Results of the toxicity study (% of survival referred to the control) after 24 hours contact of HeLa cells with 
ethanol and a CLO solution in ethanol, NLC and CLO-NLC dispersions, NLC and CLO-NLC-S gels, an aqueous 
solution of Poloxamer 24% w/w empty and CLO-containing. 
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7. CONCLUSIONS 
 
In recent years, the use of nanometric devices as delivery systems has been widely studied 
especially because of their novel engineered properties that provide medical and 
pharmaceutical benefits. Nanotechnology plays an important role in development of proper 
formulations that address the drug delivery issues related to NMEs or well-known actives with 
poor biopharmaceutical properties. Thus, nanoparticulate drug delivery systems are being used 
to alter the drug’s biopharmaceutics and pharmacokinetics such as drug absorption, distribution, 
metabolism and elimination. 
The present work focuses on the development and characterization of Nanostructured Lipid 
Carriers (NLC) and Monoolein Aqueous Dispersions (MAD) as drug delivery systems for chronic 
and recurring diseases. The obtained results permitted to better understand structure and 
behaviours of these complex carrier systems. 
 
7.1 NLC AND MAD FOR THE DELIVERY OF BROMOCRIPTINE 
The investigation reported in chapter 4 describes a formulative study for the development of 
innovative drug delivery systems for an old antiparkinsonian drug. 
The first interest in this molecule arose from its wide therapeutic potential. BC is a dopamine 
receptor agonist used for the treatment of pituitary tumours, PD, hyperprolactinaemia, 
neuroleptic malignant syndrome and recently approved for the treatment of type 2 diabetes 
[197].  
NLC and MAD based on different lipidic components were produced and characterized, and 
their morphology and dimensional distribution investigated. BC was perfectly solubilized by the 
tristearin/tricaprin NLC mixture and encapsulated with high entrapment efficiency. X-ray 
diffraction analyses demonstrated that the presence of BC did not affect the scattering profile, 
indicating maintenance of the order inside the hydrocarbon chains.  
Like NLC, MAD represents an interesting alternative to liposomes, being characterized by a 
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higher viscous resistance to rupture and a consequent prolonged stability. 
X-ray diffraction studies revealed the presence of dispersed cubic phase particles of Pn3m and 
Im3m symmetry, in full agreement with cryo-TEM observations. In addition, these studies 
evidenced in MAD the typical liquid-like conformation of lipid molecules and the complete 
dissolution of the drug in the nanoparticles. 
Concerning the in vitro analyses, the use of different experimental approaches to determine the 
release kinetic from disperse systems can give distinct results in term of drug availability. This 
point is particularly crucial, especially if we consider that information contained in the release 
curve are generally used for the determination of the therapeutic dose (bioavailable drug) and 
for quality control to ensure batch to batch uniformity. 
Our data indicate that the in vitro release of poorly water soluble drugs (as BC used in our 
study) is more affected by the composition of the receiving phase (i.e. in term of presence of 
water miscible polar organic solvents) rather than by the experimental modality adopted for the 
in vitro determinations.  
In vivo studies showed that only BC-NLC were able to markedly attenuate motor deficit in 6-
OHDA hemilesioned rats, suggesting that NLC represent a more effective carrier to prolong the 
half-life of BC in vivo. 
 
7.2 NLC AND SLN FOR THE DELIVERY OF L-DOPA DERIVATIVES 
In chapter 5 is reported a study aimed at improve the biopharmaceutical properties of new 
synthetized LD derivatives, named Der-A, Der-B, Der-C and Der-D, by the use of NLC or SLN.  
It was possible to produce NLC for controlled release of molecules with potential activity against 
neurodegenerative diseases. All the produced formulations resulted homogeneous in terms of 
size and remain stable until two months from the preparation. Morphological characterization 
highlighted that no substantial difference characterized empty and derivatives containing NLC.  
All the derivatives used, only with the exception of Der-B, showed great yields of incorporation 
compared to the total amount of medication used for preparation. In vitro kinetics release 
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performed by equilibrium dialysis highlighted that NLC were able to release the contained 
derivatives in a controlled manner and permit to select Der-A for in vivo tests and further 
inclusion tests in SLN. In vivo tests demonstrated that the Der-A possess antiparkinson activity, 
despite the best therapy in Parkinson's disease remains the LD.  
The inclusion of Der-A in SLN was performed using three different concentrations of prodrug. All 
the obtained SLN resulted dimensionally and morphologically stable within four months. The 
determination of Der-A content allowed to highlight that only two concentrations gave good 
yields of incorporation: Der-A SLN (1x) and Der-A SLN (2x). These preparations were chosen 
for calorimetric test that showed an effective interaction between lipid phase and the prodrug. In 
vitro studies performed by dialysis method and enzymatic degradation showed that the Der-A 
SLN were able to ensure a controlled release, also thanks to the extension of the half-life of the 
prodrug. Further tests should be conducted in order to evaluate the in vivo activity of Der-A SLN 
(2x) that showed the best characteristics in these characterization studies. 
 
7.3 NLC AND MAD FOR THE DELIVERY OF CLOTRIMAZOLE 
In chapter 6, Clotrimazole, an imidazole derivative, was chosen for the inclusion in NLC or MAD, 
with the aim to improve its bioavailability and obtain a suitable mucosal formulation, after 
gelification of nanosystems.  
This study demonstrated that CLO can be incorporated both in MAD and in NLC with high 
recovery. Shelf life stability evidenced that the solid matrix of NLC enabled to control drug 
degradation better than MAD. In vitro experiments on candida cells demonstrated that CLO-
MAD and CLO-NLC exhibit a higher activity than the free drug. 
In addition rheological and diffusion studies indicated that both the matrix and the gel network of 
CLO-NLC poloxamer gel can control CLO diffusion. The gel enables to solubilize lipophilic 
drugs in an aqueous structured vehicle and to control their release.  
Micro calorimetric assays permitted to better characterize the viscosized preparations and 
confirmed that all formulated gels are able to change their structure, with a rapid passage from 
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liquid to solid (crystalline) form at a temperature lower than vaginal temperature, allowing a 
selective action in the site of application. 
Finally it is noteworthy that the production of CLO-NLC poloxamer gel is simple and suitable for 
industry scaling up. 
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